



Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT): a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003898
Article Type:	Research
Date Submitted by the Author:	08-Sep-2013
Complete List of Authors:	Nagendran, Myura; Green Templeton College, University of Oxford Harding, Daniel; Magdalen College, University of Oxford Teo, Wendy; Keble College, University of Oxford Camm, Christian; New College, University of Oxford Maruthappu, Mahiben; Center for Surgery and Public Health, 5. Brigham and Women's Hospital McCulloch, Peter; Nuffield Dept of Surgery, Nuffield Department of Surgery Hopewell, Sally; University of Oxford, Centre for Statistics in Medicine
Primary Subject Heading:	Medical publishing and peer review
Secondary Subject Heading:	Surgery
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

Only

1
2
3 **Poor adherence of randomised trials in surgery to CONSORT guidelines**
4 **for non-pharmacologic treatments (NPT): a systematic review**
5
6
7

8 Dr Myura Nagendran¹

9 Daniel Harding²

10 Wendy Teo³

11 Dr Christian Camm⁴

12 Dr Mahiben Maruthappu⁵

13 Mr Peter McCulloch⁶

14 Dr Sally Hopewell^{7,8}

- 15
16
17
18
19
20
21
22 1. Green Templeton College, University of Oxford, Oxford, UK
23 2. Magdalen College, University of Oxford, Oxford, UK
24 3. Keble College, University of Oxford, Oxford, UK
25 4. New College, University of Oxford, Oxford, UK
26 5. Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, USA
27 6. Nuffield Department of Surgery, John Radcliffe Hospital, University of Oxford, Oxford,
28 UK
29 7. Centre for Statistics in Medicine, University of Oxford, Oxford, UK
30 8. INSERM U738 Paris, France; Centre d'Épidémiologie Clinique, AP-HP (Assistance
31 Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France
32
33
34
35
36
37
38
39

40 Corresponding author:

41 Dr Myura Nagendran

42 Green Templeton College,

43 University of Oxford

44 Woodstock Road, Oxford. OX2 6HG, UK

45 E: myura.nagendran@gmail.com

46 T: +44 791 255 6717

47 F: +44 1865 274 796

48
49
50
51
52
53 Keywords: Checklist/standards, Publishing/standards, Randomized Controlled Trials,
54 Reference Standards
55
56
57

58 Word count: 2,955
59
60

ABSTRACT

Objective

To systematically assess adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT). Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials. The CONSORT-NPT extension was designed to address these issues but adherence in both medical and surgical journals has not been assessed.

Design

Systematic review.

Sample

We identified eight general medical and eight surgical journals, indexed in PubMed and published in 2011, with the highest impact factors in their respective categories.

Main outcomes

Adherence to CONSORT Statement and CONSORT-NPT extension items.

Results

We identified 54 surgical trials (22 published in medical journals and 32 in surgical journals). There were eight items for which there was less than 30% overall compliance (seven were specific to the CONSORT-NPT extension). These seven items related to: a full description of the care providers, centers and blinding status in the abstract (n=7/54, 13%), eligibility criteria for centers performing the interventions (n=13/54, 24%), how adherence of care providers with the protocol was assessed or enhanced (n=7/54, 13%), how clustering by care providers or centers was addressed as it relates to sample size (n=3/54, 6%), how care providers were allocated to each group (n=9/54, 17%), how clustering by care providers or centers was addressed as it relates to statistical methods (n=2/54, 4%), a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group (n=0/54, 0%).

Conclusions

Adherence of surgical trials to CONSORT-NPT extension items is much poorer than to the standard CONSORT Statement. Adherence also appears to be superior in general medical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

compared to surgical journals. Raising awareness and conducting qualitative research to identify areas for specific intervention will be important going forward.

For peer review only

ARTICLE SUMMARY

Article focus

- Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials.
- The CONSORT-NPT extension was designed to address these issues but adherence in both medical and surgical journals has not been assessed.
- Our objective was to carry out a systematic review of adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT).

Key messages

- Adherence of surgical trials to CONSORT-NPT extension items is much poorer than to the standard CONSORT Statement. Adherence also appears to be superior in general medical compared to surgical journals.
- Raising awareness and conducting qualitative research to identify areas for specific intervention will be important going forward.

Strengths and limitations of this study

- This study is the first to assess surgical trials reported in both general medical and surgical journals for adherence to the CONSORT-NPT extension.
- However, the final cross-sectional sample was small with only 54 trials. This precluded a detailed statistical analysis.

INTRODUCTION

Randomized controlled trials (RCTs) are designed to determine the association between efficacy of a treatment and clinical outcome. In this regard, they are considered the gold standard of healthcare evidence and the resulting conclusions can significantly affect clinical practice.¹ It is therefore imperative that trials are well designed and correctly executed. However, it is equally important that trials are fully and transparently reported to allow proper critical appraisal by the scientific community.

Key information is often missing from published trials^{2,3} and there may be a correlation between incomplete reporting and poor trial methodology.⁴⁻⁶ Such missing information can include items as crucial as sample size, details of randomisation, blinding and the choice of primary outcome. In response to this problem, the Consolidated Standards of Reporting Trials (CONSORT) statement was launched in 1996 and aimed to provide a checklist of essential items that authors should report when publishing their study.⁷ The CONSORT Statement was updated in 2001 and more recently in 2010 and is now endorsed by more than 600 leading medical journals.^{8,9} Whilst the CONSORT Statement has been credited with improving the reporting standards of RCTs,¹⁰ many recent studies have highlighted remaining deficiencies in both medical¹¹⁻¹⁴ and surgical literature.¹⁵⁻¹⁸

Surgical trials are often considered more difficult to design and execute than pharmacological trials.¹⁹ Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials such as difficulty in blinding patients and outcome assessors, variation in surgical technique and experience of operators. In 2008 an extension to the CONSORT Statement was published providing specific recommendations for the reporting of RCTs of non-pharmacological treatment

1
2
3 (CONSORT-NPT).²⁰ Examples of added items include specifying the eligibility criteria for
4
5 centres performing the intervention and how care providers are allocated to each trial group.
6

7
8 The aim of this study was to analyse the quality of reporting of RCTs in surgery
9
10 published in both medical and surgical journals based on the reporting criteria included in the
11
12 2010 CONSORT Statement and CONSORT-NPT extension.
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

METHODS

Search Strategy

We identified the eight general medical and eight surgical journals with the highest ISI impact factors from the “Medicine, General and Internal” and “Surgery” categories respectively of the 2011 Journal Citation Reports provided by Thomson Reuters.²¹ All 16 journals (see appendix S1) are indexed on PubMed and a search was then conducted to identify reports of RCTs published in these 16 journals. The search (see appendix S2) combined the ‘Cochrane Highly Sensitive Search Strategy for identifying randomized trials’²² with the publication year 2011 and journal name (conducted in March 2012). Additionally, the terms “surgery OR surgical OR surgeon” were added when searching the eight general medical journals to restrict results to RCTs in surgery. The search was conducted independently for each journal. All titles and abstracts retrieved from the search were assessed for eligibility by the authors (MN, MM, DH, WT, FC) such that each record was reviewed independently by at least two authors. Studies in which it was not clear whether the inclusion criteria had been met were reviewed in full text and discrepancies were resolved by consensus. All journals included in our sample are published in English.

Inclusion and exclusion criteria

We defined a randomized trial as a prospective study assessing health-care interventions in human participants who were randomly allocated to study groups. Studies were considered eligible for inclusion if they were: (i) reports of a randomized controlled trial, (ii) published in 2011 (either print or online e-publication during 2011), and (iii) the primary aim of the study was considered an interventional therapy. For the purposes of this study, an interventional therapy was defined as a therapy involving (a) some element of

1
2
3 invasion or trauma to the body and (b) the requirement for operator skill to achieve a
4
5 successful requirement and with the exception of an intervention being used purely to deliver
6
7 a pharmacological treatment (i.e. catheter delivered drug) (see appendix S2). We excluded
8
9 reports where (i) one of the trial arms did not contain an interventional therapy as defined
10
11 above, (ii) a drug was the primary intervention, even in a surgical population (e.g.
12
13 chemotherapy for ovarian cancer) or (iii) the RCT had been previously published and the
14
15 current report was merely a follow-up or subgroup analysis using the same cohort of patients.
16
17
18
19

20 21 **Data extraction**

22
23 We created a modified version of the CONSORT checklist which contained all of the
24
25 2008 CONSORT-NPT checklist items and all of the standard 2010 CONSORT checklist
26
27 items. The resulting checklist had a total of 42 items (see appendix S3). Two authors (DH,
28
29 WT) independently assessed each of the eligible reports against this checklist. Reports were
30
31 also scored by the same authors for trial quality using the extended version of the Linde
32
33 Internal Validity Scale (ELIVS) (see table 3, appendix S2). The ELIVS scoring system used
34
35 in this study was developed from initial work by Jadad et al.²³ and Linde et al.²⁴ It measures
36
37 the following quality domains: treatment allocation, randomisation method, allocation
38
39 concealment, post-randomisation baseline comparison, blinding, handling and reporting of
40
41 withdrawals and intention to treat analysis. Any discrepancies were resolved by consensus.
42
43 Inter-observer analysis was assessed by calculating the Cohen's kappa score. Extraction of
44
45 data from studies was carried out in Microsoft Excel (2010, Microsoft Corporation,
46
47 Redmond, WA, USA) using a pre-piloted form that was tested on two randomly selected
48
49 studies from 2010.
50
51
52

53
54 For each report, we also extracted the following data: the number of authors, the
55
56 continent where the study was conducted, multicentre status, number of study participants and
57
58
59
60

1
2
3 reporting of ethics review and conflict of interest. For each journal included, we obtained the
4
5 ISI 2011 impact factor and whether or not the journal endorsed (e.g. recommended or
6
7 required) the CONSORT Statement and CONSORT-NPT extension (information obtained in
8
9 2012).

14 **Author survey**

15
16 We also emailed the corresponding author for each included report, with five
17
18 questions relating to the CONSORT-NPT extension in April 2013. The questions were: (i)
19
20 Are you currently aware of the 2008 CONSORT-NPT extension? (ii) Were you aware of the
21
22 2008 CONSORT-NPT extension at the time of submission? (iii) Did the journal editorial
23
24 staff mention the CONSORT-NPT extension to you during the editorial process (other than
25
26 the instructions for authors on the journal website)? Did the journal peer reviewers mention
27
28 the CONSORT-NPT extension to you during the review process? (v) Would your choice of
29
30 journal for submission be affected by whether or not the journal mentions the CONSORT-
31
32 NPT extension in their online instructions for authors? Each answer could be reported as
33
34 'yes', 'no' or 'cannot remember/unsure'.
35
36
37
38
39
40

41 **Outcomes and statistical analysis**

42
43 Our primary outcome measure was adherence measured as the proportion of articles
44
45 reporting each individual CONSORT and CONSORT-NPT checklist item. We also compared
46
47 any differences in adherence between reports published in general medical with those
48
49 published in surgical journals. All analyses were performed using STATA statistical software
50
51 version 12.1 (College Station, TX).
52
53
54
55
56
57
58
59
60

RESULTS

Our initial PubMed searches identified 831 possible reports, of which 771 were excluded as ineligible based on the information reported in the title and abstract. Sixty full text articles were retrieved for further assessment of which six were excluded because they were reports of previously published trials. This left 54 RCTs with a combined total of 16,338 patients from 11 journals that met the inclusion criteria (summarised in figure 1).

The baseline characteristics of the included trials are shown in table 1. The medical journals had a tendency toward higher numbers of patients and a larger number of authors as well as a greater proportion of multicentre, higher quality (as measured by the ELIVS scale) trials. The requirement for CONSORT adherence was variable between the medical and surgical journals. Overall, only around half of the articles were published in a journal that required (26/54 studies; 48%) CONSORT adherence (table 1). The percentage of articles published in a journal that mentioned CONSORT in the instructions to peer reviewers (9/54 studies; 27%) was lower.

Table 1. Baseline characteristics of included studies.

	Overall (n=54)	Medical (n=22)	Surgical (n=32)
Trial characteristics			
No. of patients, median (IQR)	177 (110-410)	363 (195-757)	129 (71-177)
No. of authors, median (IQR)	9 (6-12)	12 (9-17)	7 (6-11)
Impact factor, median (IQR)	7.5 (4.5-30.0)	33.6 (30.0-53.5)	4.6 (4.4-7.5)
Multicentre trials, no. (%)	28 (52)	20 (91)	8 (25)
Ethics review, no. (%)	54 (100)	22 (100)	32 (100)
COI declared, no. (%)	47 (87)	22 (100)	25 (78)
ELIVS Quality score, mean (SD)	5.1 (1.5)	5.8 (1.4)	4.5 (1.3)
Journal CONSORT endorsement			
CONSORT required in ITA, no. (%)	26 (48)	13 (59)	13 (41)
CONSORT recommended in ITA, no. (%)	28 (52)	9 (41)	19 (59)
CONSORT mentioned in ITPR, no. (%)	9 (27)	6 (27)	3 (10)

Adherence of trials to the modified CONSORT checklist was variable ranging from 0-100% for each of the individual 42 checklist items (table 2). The highest scoring trials satisfied 36 of 42 items while the lowest scoring trial satisfied only 18 items (median 27, interquartile range 23-31). There were eight items for which there was less than 30% overall compliance (indicated with an asterisk in table 2). Of these eight items, seven were specific to the CONSORT-NPT extension. These seven items related to the following topics: a full description of the care providers, centers and blinding status in the abstract (item 1b; adherence 13%), eligibility criteria for centers performing the interventions (item 4b; adherence 24%), how adherence of care providers with the protocol was assessed or enhanced (item 5c; adherence 13%), how clustering by care providers or centers was addressed as it relates to sample size (item 7a; adherence 6%), how care providers were allocated to each group (item 8b; adherence 17%), how clustering by care providers or centers was addressed as it relates to statistical methods (item 12b; adherence 4%), a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group (item 15b; adherence 0%). The non CONSORT-NPT item with less than 30% adherence related to the presentation of both absolute and relative effect sizes for binary outcomes (item 17b; adherence 28%).

Table 2. Adherence of studies to modified CONSORT-NPT checklist.

CONSORT Number	Point	Overall adherence, no. (%)	Medical adherence, no. (%)	Surgical adherence, no. (%)
1a	Title and abstract	46 (85)	17 (77)	29 (91)
1b		7 (13)*	7 (32)	0
2a	Background and objectives	54 (100)	22 (100)	32 (100)
2b		54 (100)	22 (100)	32 (100)
3a	Trial design	22 (41)	14 (64)	8 (25)
3b		54 (100)	22 (100)	32 (100)
4a	Participants	54 (100)	22 (100)	32 (100)
4b		13 (24)*	7 (32)	6 (19)

5		48 (89)	19 (86)	29 (91)
5a	Interventions	39 (72)	20 (91)	19 (59)
5b		50 (93)	20 (91)	30 (94)
5c		7 (13)*	6 (27)	1 (3)
6a	Outcomes	48 (89)	22 (100)	26 (81)
6b		54 (100)	22 (100)	32 (100)
7a	Sample size	3 (6)*	2 (9)	1 (3)
7b		52 (96)	22 (100)	30 (94)
8a	Randomisation sequence generation	30 (56)	12 (55)	18 (56)
8b		9 (17)*	2 (9)	7 (22)
9	Allocation concealment mechanism	28 (52)	17 (77)	11 (34)
10	Randomisation implementation	18 (33)	13 (59)	5 (16)
11a	Blinding	29 (54)	16 (73)	13 (41)
11b		30 (56)	16 (73)	14 (44)
12a	Statistical methods	54 (100)	22 (100)	32 (100)
12b		2 (4)*	0	2 (6)
13a	Participant flow	0*	0	0
13b		51 (94)	22 (100)	29 (91)
New	Implementation of intervention	38 (70)	12 (55)	26 (81)
14a	Recruitment	48 (89)	22 (100)	26 (81)
14b		51 (94)	22 (100)	29 (91)
15a	Baseline data	52 (96)	22 (100)	30 (94)
15b		0*	0	0
16	Numbers analysed	52 (96)	22 (100)	30 (94)
17a	Outcomes and estimation	21 (39)	18 (82)	3 (9)
17b		15 (28)*	14 (64)	1 (3)
18	Ancillary analyses	42 (78)	20 (91)	22 (29)
19	Harms	51 (94)	21 (95)	30 (94)
20	Limitations	35 (65)	19 (86)	16 (50)
21	Generalisability	24 (44)	14 (64)	10 (31)
22	Interpretation	51 (94)	22 (100)	29 (91)
23	Registration	49 (91)	22 (100)	27 (84)
24	Protocol	25 (46)	18 (82)	7 (22)
25	Funding	40 (74)	22 (100)	18 (56)

We did not statistically compare the different adherence rates between the trials published in general medical and surgical journals as originally planned owing to the small

sample size and the large number of hypotheses that could potentially be tested (all 42 checklist items). However, in comparing the percentage adherence rates between the two journal groups, general medical journals typically generated superior adherence. There were three exceptions where surgical journal adherence was more than 10% superior to trials published in medical journals (item 1a, identification as a randomised trial in the title; item 8b, allocation of care providers to each group; item “New”, implementation of intervention as it was implemented).

We contacted the lead author for each of the 54 reports to ask about their awareness of CONSORT-NPT. Only 17 authors replied (31% response rate) and so we were therefore not able to perform formal quantitative analysis on the survey results. Based on the replies we received, approximately a third of respondents were aware of CONSORT-NPT at the time of submission, while two thirds are aware of its existence now (table 3). Given the time lapse between manuscript submission and our short survey, about a quarter of respondents were unable to remember whether journal editors and peer reviewers had mentioned CONSORT-NPT during the review process. Finally, a third of respondents agreed that their choice of journal for submission would be affected by whether or not CONSORT-NPT was mentioned in the instructions for authors section of the journal (we did not ascertain the direction of this preference).

Table 3. Results from survey of corresponding authors.

Question no.	Topic	Yes	No	Can't remember / Not sure
1	Currently aware of NPT	11 (65%)	5 (35%)	0
2	Aware of NPT at submission	6 (35%)	10 (65%)	0

3	NPT mentioned by editorial staff	2 (12%)	10 (59%)	5 (29%)
4	NPT mentioned by peer-reviewers	1 (6%)	11 (71%)	4 (24%)
5	NPT endorsement by journal would affect submission choice	5 (29%)	10 (65%)	1 (6%)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Summary of main findings

In this study, we included 54 reports of surgical RCTs published in 2011 from a cross sectional sample of 11 medical and surgical journals. We assessed these reports for their adherence to a combined CONSORT and CONSORT-NPT checklist with two main findings. Firstly, reporting adherence of surgical RCTs to the CONSORT-NPT extension was much poorer than adherence to the main CONSORT checklist. Secondly, general medical journals were broadly superior in their NPT reporting as compared to surgical journals. To our knowledge this is the first study to demonstrate this difference between journal types for the CONSORT-NPT extension and one of only a few studies to document NPT adherence.

Comparison with the literature

The findings from our study are in agreement with the existing literature on CONSORT adherence. A recent systematic review of 53 studies found that reporting has remained sub-optimal despite the CONSORT Statement having been active in various iterations since 1996.²⁵ However, the authors suggest that journal endorsement does appear to have had a positive impact on adherence. One review that included a comparison between surgical RCTs published in both medical and surgical journals also found that adherence to CONSORT items was significantly superior in medical journals.¹⁶ Both of these articles assessed adherence only to the standard CONSORT Statement. A more recent study that assessed adherence specifically to the CONSORT-NPT extension checklist both before (2004) and after (2010) the checklist was launched found little improvement in NPT specific items (although these have had less time for absorption by the community than the standard

1
2
3 CONSORT Statement).¹⁷ These were reported in less than 50% of trials during 2010. The
4
5 adherence rates in our study for similar NPT items were even lower.
6
7

8 9 10 **Limitations**

11
12 Our study has several limitations. First, we only included studies published in high
13
14 impact English language journals indexed in PubMed in 2011. In combination with our strict
15
16 inclusion criteria on what constituted a surgical intervention, this led to a small sample of
17
18 only 54 RCTs. We were consequently unable to perform detailed statistical analysis on
19
20 individual checklist items. The decision to limit the cross-sectional sample to one year was
21
22 made on pragmatic grounds owing to the very lengthy process of scoring the RCTs against
23
24 the checklist items. It was also for this reason that we restricted the number of journals we
25
26 searched to the top eight impact factor journals within each specialty.
27
28

29
30 A second limitation pertains to the cross-sectional nature of our study. We are unable
31
32 to suggest whether any progress is being made in adherence to the NPT extension. As
33
34 previously described, an interrupted before-after study found only moderate improvement
35
36 between 2004 and 2010.¹⁷ Our author survey suggested that there had been an increase in the
37
38 proportion of authors who were aware of the existence of the CONSORT-NPT extension
39
40 between the time of submission and now. Whether this translates to improved adherence at
41
42 the current time is unknown.
43
44

45
46 A final limitation concerns the author survey. We were restricted in our ability to
47
48 analyse this data by the poor response rate and the significant time lag between submission of
49
50 the RCTs (circa 2010) and distribution of the survey to corresponding authors in 2013.
51
52

53 54 **Implications for authors and journals**

55
56
57
58
59
60

1
2
3 The CONSORT-NPT items with the poorest adherence were predominantly related to
4 details on the implementation of the intervention, the providers (surgeons) and the centres.
5
6 The CONSORT-NPT extension was specifically created to encourage reporting of these
7
8 intervention specific items given their importance in generalising a trial intervention to non-
9
10 trial populations. As an example, two early symptomatic carotid surgery trials, NASCET and
11
12 ACAS,^{26,27} both had restrictive criteria for selecting which surgeons and centres were
13
14 permitted to perform the intervention. Consequently, one large national cohort study that
15
16 followed on from these trials did not see as large an improvement in patient outcomes.²⁸ The
17
18 study pointed out that less than 4% of all US hospitals providing carotid endarterectomy were
19
20 included in NASCET and indeed that Medicare patients treated at trial hospitals had a lower
21
22 risk of dying than at other hospitals.
23
24
25
26

27
28 We might anecdotally expect CONSORT-NPT items to be more vigorously enforced
29
30 by surgical journals. This is on the basis that surgeons (who would likely form a greater
31
32 component of the journal's editorial board and peer reviewers) would be more familiar with
33
34 the multiple elements of the intervention and the importance of these elements in their own
35
36 practice. Naturally therefore, they might be keener to see these reported more thoroughly in
37
38 manuscripts reporting RCTs. Our results appear to suggest the opposite in that general
39
40 medical journals displayed superior NPT adherence. It is difficult to ascertain whether this
41
42 finding is confounded by the much larger impact factor of the general medical journals in our
43
44 sample and the potential for a self-fulfilling prophecy (i.e. better reported trials opt
45
46 preferentially to try and publish in the high impact medical journals rather than such RCTs
47
48 being well reported as a prime result of enforcement by the medical journal).
49
50
51

52 The literature on CONSORT adherence failures is extensive and is developing
53
54 similarly for the CONSORT-NPT extension.²⁵ Now that the problem has been well
55
56 documented, the focus will likely shift towards identifying actionable areas for intervention.
57
58
59
60

1
2
3 In the first instance, we suggest that qualitative interviews and focus groups with
4 stakeholders at surgical trials departments will be important. Identifying the precise barriers
5 to adherence will better inform the community on how best to improve reporting and where
6 the greatest impact can be had. For example, does the problem lie with restrictive word
7 counts, lack of time, lack of enforcement or simply just lack of awareness? How far would
8 journals be prepared to go with enforcement? Would this be a viable option for smaller
9 impact journals, perhaps fearful of driving authors away by enforcing reporting guidelines
10 too rigidly?
11
12
13
14
15
16
17
18
19

20
21 These are all important questions that could be further elucidated by qualitative
22 research in this field. New guidance on surgical RCT methodology²⁹ and calls for greater
23 investment in surgical research³⁰ should be combined with greater awareness of the
24 CONSORT-NPT extension. Reporting standards, like trial design are not static but need to
25 adapt to the changing research landscape. CONSORT therefore needs to respond to proposals
26 for new reporting standards such as those proposed by the IDEAL Collaboration²⁹ in future
27 NPT extensions. Notably, the All Trials movement pushing for transparency of
28 pharmaceutical trials has garnered much attention from the public and press over recent
29 months.³¹ This momentum has added weight to the growing call for thorough reporting to be
30 considered a core duty of clinician researchers rather than just a desirable trait.
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Conclusion**

46
47 The findings from this cross sectional review of surgical trials suggest that adherence
48 to CONSORT-NPT extension items is much poorer than to the standard CONSORT
49 Statement. Adherence also appears to be superior in general medical compared to surgical
50 journals. A combination of more qualitative research to identify areas for specific
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

intervention and a continuing effort to raise awareness of the CONSORT-NPT extension among stakeholders will be important going forward.

For peer review only

ACKNOWLEDGEMENTS

None.

COMPETING INTERESTS

SH, Centre for Statistics in Medicine, is a member of the CONSORT group. PM is the Chair of the IDEAL Collaboration.

FUNDING

No funding was received from any source for any part of this work.

References

1. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. *J Clin Epidemiol*. 1999; **52**(6): 487-97.
2. Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I. Size and quality of randomised controlled trials in head injury: review of published studies. *BMJ*. 2000; **320**(7245): 1308-11.
3. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. *BMJ*. 1998; **317**(7167): 1181-4.
4. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. *JAMA*. 2002; **287**(21): 2801-4.
5. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ*. 2001; **323**(7303): 42-6.
6. Montori VM, Wang YG, Alonso-Coello P, Bhagra S. Systematic evaluation of the quality of randomized controlled trials in diabetes. *Diabetes Care*. 2006; **29**(8): 1833-8.
7. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA*. 1996; **276**(8): 637-9.
8. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010; **340**: c869.
9. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet*. 2001; **357**(9263): 1191-4.
10. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. *Syst Rev*. 2012; **1**: 60.
11. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to

- 1 the Consolidated Standards of Reporting Trials (CONSORT) checklist. *Control Clin Trials*. 2002; **23**(4):
2 380-8.
3
4
5 12. Haidich AB, Birtsou C, Dardavessis T, Tirodimos I, Arvanitidou M. The quality of safety
6 reporting in trials is still suboptimal: survey of major general medical journals. *J Clin Epidemiol*. 2011;
7 **64**(2): 124-35.
8
9
10 13. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading
11 medical journals since the revised CONSORT statement. *Contemp Clin Trials*. 2005; **26**(4): 480-7.
12
13 14. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of
14 randomized trials: a comparative before-and-after evaluation. *JAMA*. 2001; **285**(15): 1992-5.
15
16 15. Agha R, Cooper D, Muir G. The reporting quality of randomised controlled trials in surgery: a
17 systematic review. *Int J Surg*. 2007; **5**(6): 413-22.
18
19 16. Balasubramanian SP, Wiener M, Alshameeri Z, Tiruvoipati R, Elbourne D, Reed MW. Standards
20 of reporting of randomized controlled trials in general surgery: can we do better? *Ann Surg*. 2006; **244**(5):
21 663-7.
22
23 17. Gray R, Sullivan M, Altman DG, Gordon-Weeks AN. Adherence of trials of operative
24 intervention to the CONSORT statement extension for non-pharmacological treatments: a comparative
25 before and after study. *Ann R Coll Surg Engl*. 2012; **94**(6): 388-94.
26
27 18. Sinha S, Ashby E, Jayaram R, Grocott MP. Quality of reporting in randomized trials published in
28 high-quality surgical journals. *J Am Coll Surg*. 2009; **209**(5): 565-71 e1.
29
30 19. McCulloch P, Taylor I, Sasako M, Lovett B, Griffin D. Randomised trials in surgery: problems
31 and possible solutions. *BMJ*. 2002; **324**(7351): 1448-51.
32
33 20. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to
34 randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med*. 2008;
35 **148**(4): 295-309.
36
37 21. Thomson-Reuters. ISI Web of Knowledge. 2012 [cited 18 September 2012]; Available from:
38 <http://wok.mimas.ac.uk/>
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011.
 23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996; **17**(1): 1-12.
 24. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. *BMJ*. 1996; **313**(7052): 253-8.
 25. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *Cochrane Database Syst Rev*. 2012; **11**: MR000030.
 26. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med*. 1991; **325**(7): 445-53.
 27. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA*. 1995; **273**(18): 1421-8.
 28. Wennberg DE, Lucas FL, Birkmeyer JD, Bredenberg CE, Fisher ES. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. *JAMA*. 1998; **279**(16): 1278-81.
 29. Cook JA, McCulloch P, Blazeby JM, Beard DJ, Marinac-Dabic D, Sedrakyan A. IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage. *BMJ*. 2013; **346**: f2820.
 30. McCulloch P. How to improve surgical research. *BMJ*. 2011; **343**: d4121.
 31. Brown T. It's Time for AllTrials Registered and Reported. *Cochrane Database Syst Rev*. 2013; **5**: ED000057.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of study selection.
176x133mm (72 x 72 DPI)

Review only

APPENDIX S1

Search strategy for medical journals

Databases: **PubMed** <1948 to Present>

Search Strategy:

1	randomized controlled trial [pt]	(319493)
2	controlled clinical trial [pt]	(83422)
3	randomized [tiab]	(258027)
4	placebo [tiab]	(138836)
5	drug therapy [sh]	(1500313)
6	randomly [tiab]	(177741)
7	trial [tiab]	(298335)
8	groups [tiab]	(1179377)
9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	(2938926)
10	animals [mh] NOT humans [mh]	(3648479)
11	#9 NOT #10	(2515800)
12	2011[dp]	(980498)
13	"N Engl J Med"[Journal]	(66892)
14	(Surgery OR Surgical OR Surgeon)	(3293015)
15	#11 AND #12 AND #13 AND #14	(54)

NB: searches 1 to 11 are taken directly from the Cochrane Handbook, box 6.4a. These steps form the 'Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format'.

COMPRESSED SEARCH – New England Journal of Medicine (NEJM) – 54 RESULTS

((randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])) AND (2011[dp]) AND (surgery OR surgical OR surgeon) AND ("N Engl J Med"[Journal])

Search strategy for surgical journals

Databases: **PubMed** <1948 to Present>

Search Strategy:

1	randomized controlled trial [pt]	(319493)
2	controlled clinical trial [pt]	(83422)
3	randomized [tiab]	(258027)
4	placebo [tiab]	(138836)
5	drug therapy [sh]	(1500313)
6	randomly [tiab]	(177741)
7	trial [tiab]	(298335)
8	groups [tiab]	(1179377)
9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	(2938926)
10	animals [mh] NOT humans [mh]	(3648479)
11	#9 NOT #10	(2515800)
12	2011[dp]	(980498)
13	"Ann Surg"[Journal]	(27081)
14	#11 AND #12 AND #13	(109)

NB: searches 1 to 11 are taken directly from the Cochrane Handbook, box 6.4a. These steps form the 'Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format'.

COMPRESSED SEARCH – Annals of Surgery – **109 RESULTS**

((randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])) AND (2011[dp]) AND ("Ann Surg"[Journal])

APPENDIX S2**CRITERIA FOR SELECTING STUDIES****INCLUSION CRITERIA:**

- Randomized clinical trial
- Human subjects
- Published in 2011 (this can include EITHER print or e-publication during 2011)
- Primary aim of study considers an interventional therapy
 - o For the purpose of this study, this is defined as a therapy involving:
 - Some element of invasion or trauma to the body
 - The requirement for operator skill to achieve a successful requirement
 - With the exception of an intervention being used purely to deliver a pharmacologic treatment (i.e. catheter delivered drug)

EXCLUSION CRITERIA:

- One of the trial arms does not contain an interventional therapy as defined above
- Drug treatment as the primary intervention, even in a surgical population (e.g. chemotherapy for ovarian cancer)
- Trial has previously been reported

EXAMPLES of excludable studies:

- Drug/fluid/blood in both arms (no interventional therapy)
- Psychological/educational training in both arms (no interventional therapy)
- Intervention in one arm but only used to deliver a drug (e.g. catheter infusion of local anaesthetic or delivery of thrombolysis)
- Endoscopy, colonoscopy enteroscopy in both arms with no explicit intention stated to use intervention therapy (i.e. procedure was intended for imaging purposes)
- Subgroup analysis of a previously reported trial
- Long term follow-up data of a previously reported trial

Journal Information

Journal	Abbreviated code	2011 ISI Impact Factor	Number of Results	Number of included RCTs
MEDICAL				
New England Journal of Medicine	NEJM	53.298	54	7
The Lancet	LANC	38.278	58	6
Journal of the American Medical Association	JAMA	30.026	41	4
Annals of Internal Medicine	ANIM	16.733	19	1
PLOS Medicine	PLOS	16.269	4	2
BMJ	BMJ	14.093	26	2
Archives of Internal Medicine	ARIM	11.462	14	0
Canadian Medical Association Journal	CMAJ	8.217	12	0
SURGICAL				
Annals of Surgery	ANSU	7.492	109	11
American Journal of Transplantation	AJT	6.394	76	0
Endoscopy	ENDO	5.210	63	3
Journal of Neurology, Neurosurgery and Psychiatry	JNNP	4.764	93	2
British Journal of Surgery	BJS	4.606	121	13
Journal of the American College of Surgeons	JACS	4.549	59	0
American Journal of Surgical Pathology	AJSP	4.352	24	0
Archives of Surgery	ARCH	4.239	58	3
TOTAL			831	54

APPENDIX S3

Modified CONSORT Number	Point	Guideline to use when scoring	Present in 2008 NPT?	2008 NPT Extension points to be aware of when scoring
1a	Title and abstract	2010	Yes (combined a/b)	In the abstract, description of the experimental treatment, comparator, care providers, centers, and blinding status
1b				
2a	Background and objectives	2010	Yes (combined a/b)	N/A
2b				
3a	Trial design	2010	No	N/A
3b				
4a	Participants	2010	Yes (combined a/b)	When applicable, eligibility criteria for centers and those performing the interventions
4b				
5	Interventions	2010	Yes (split a/b/c)	Precise details of both the experimental treatment and comparator
5a				Description of the different components of the interventions and, when applicable, descriptions of the procedure for tailoring the interventions to individual participants
5b				Details of how the interventions were standardized
5c				Details of how adherence of care providers with the protocol was assessed or enhanced
6a	Outcomes	2010	Yes (combined a/b)	N/A
6b				
7a	Sample size	2010	Yes (combined a/b)	When applicable, details of whether and how the clustering by care providers or centers was addressed
7b				
8a	Randomisation sequence generation	2010	Yes (combined a/b)	When applicable, how care providers were allocated to each trial group
8b				
9	Allocation concealment mechanism	2010	Yes	N/A
10	Randomisation implementation	2010	Yes	N/A

Modified CONSORT Number	Point	Guideline to use when scoring	Present in 2008 NPT?	2008 NPT Extension points to be aware of when scoring
11a	Blinding	2010	Yes (split a/b)	Whether or not those administering co-interventions were blinded to group assignment
11b				If blinded, method of blinding and description of the similarity of interventions
12a	Statistical methods	2010	Yes (combined a/b)	When applicable, details of whether and how the clustering by care providers or centers was addressed
12b				
13a	Participant flow	2010	Yes (combined a/b)	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center
13b				
New in NPT	Implementation of intervention	<u>2008 NPT</u>	Yes	Details of the experimental treatment and comparator as they were implemented
14a	Recruitment	2010	Yes (combined a/b)	N/A
14b				
15a	Baseline data	2010	Yes	(2010 Point 15) N/A
15b		<u>2008 NPT</u>	Yes	(2008 NPT Extension) When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group
16	Numbers analysed	2010	Yes	N/A
17a	Outcomes and estimation	2010	Yes (combined a/b)	N/A
17b				
18	Ancillary analyses	2010	Yes	N/A
19	Harms	2010	Yes	N/A
20	Limitations	2010	No	N/A
21	Generalisability	2010	Yes	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial

22	Interpretation	2010	Yes	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group
23	Registration	2010	No	N/A
24	Protocol	2010	No	N/A
25	Funding	2010	No	N/A

Tables 1 and 2. Tables showing the modified CONSORT scoring checklist to take into account the 2008 NPT extension guidelines whilst scoring against the general points in the 2010 standard CONSORT statement

ELIVS Number	Point	Further detail
E1	Treatment allocation	Was it randomised?
E2	Randomisation method	Appropriate method of randomisation described
E3	Allocation concealment	Appropriate steps taken to conceal allocation sequence
E4	Post-randomisation baseline comparison	Usually located in a table. Showing both groups are similar post randomisation for all known prognostically important factors
E5	Patients blinded	Method of blinding described and is appropriate
E6	Evaluators blinded	Method of blinding described and is appropriate
E7i	Handling and reporting of withdrawals	Full accounting for all patients who entered the trial
E7ii	Intention to treat analysis	Per protocol analysis can be provided in addition but there must also be ITT analysis

Table 3. Extended Linde Internal Validity Scale



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n/a
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix S2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	n/a
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	n/a

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	n/a
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	n/a
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	n/a
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	n/a
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	n/a
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.



Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT): a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003898.R1
Article Type:	Research
Date Submitted by the Author:	16-Nov-2013
Complete List of Authors:	Nagendran, Myura; Green Templeton College, University of Oxford Harding, Daniel; Magdalen College, University of Oxford Teo, Wendy; Keble College, University of Oxford Camm, Christian; New College, University of Oxford Maruthappu, Mahiben; Center for Surgery and Public Health, 5. Brigham and Women's Hospital McCulloch, Peter; Nuffield Dept of Surgery, Nuffield Department of Surgery Hopewell, Sally; University of Oxford, Centre for Statistics in Medicine
Primary Subject Heading:	Medical publishing and peer review
Secondary Subject Heading:	Surgery
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

Only

1
2
3 **Poor adherence of randomised trials in surgery to CONSORT guidelines**
4 **for non-pharmacologic treatments (NPT): a cross-sectional study**
5
6
7

8 Dr Myura Nagendran¹

9 Daniel Harding²

10 Wendy Teo³

11 Dr Christian Camm⁴

12 Dr Mahiben Maruthappu⁵

13 Mr Peter McCulloch⁶

14 Dr Sally Hopewell^{7,8}

- 15
16
17
18
19
20
21
22 1. Green Templeton College, University of Oxford, Oxford, UK
23 2. Magdalen College, University of Oxford, Oxford, UK
24 3. Keble College, University of Oxford, Oxford, UK
25 4. New College, University of Oxford, Oxford, UK
26 5. Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, USA
27 6. Nuffield Department of Surgery, John Radcliffe Hospital, University of Oxford, Oxford,
28 UK
29 7. Centre for Statistics in Medicine, University of Oxford, Oxford, UK
30 8. INSERM U738 Paris, France; Centre d'Épidémiologie Clinique, AP-HP (Assistance
31 Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France
32
33
34
35
36
37
38
39

40 Corresponding author:

41 Dr Myura Nagendran

42 Green Templeton College,

43 University of Oxford

44 Woodstock Road, Oxford. OX2 6HG, UK

45 E: myura.nagendran@imperial.ac.uk

46 T: +44 791 255 6717

47 F: +44 1865 274 796

48
49
50
51
52
53 Keywords: Checklist/standards, Publishing/standards, Randomized Controlled Trials,
54 Reference Standards
55
56
57

58 Word count: 2,961
59
60

ABSTRACT

Objective

To systematically assess adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT). Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials. The CONSORT-NPT extension was designed to address these issues but adherence in both medical and surgical journals has not been assessed.

Design

Cross-sectional study.

Sample

We identified eight general medical and eight surgical journals, indexed in PubMed and published in 2011, with the highest impact factors in their respective categories.

Main outcomes

Adherence to CONSORT Statement and CONSORT-NPT extension items.

Results

We identified 54 surgical trials (22 published in medical journals and 32 in surgical journals). There were eight items for which there was less than 30% overall compliance (seven were specific to the CONSORT-NPT extension). These seven items related to: a full description of the care providers, centers and blinding status in the abstract (n=7/54, 13%), eligibility criteria for centers performing the interventions (n=13/54, 24%), how adherence of care providers with the protocol was assessed or enhanced (n=7/54, 13%), how clustering by care providers or centers was addressed as it relates to sample size (n=3/54, 6%), how care providers were allocated to each group (n=9/54, 17%), how clustering by care providers or centers was addressed as it relates to statistical methods (n=2/54, 4%), a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group (n=0/54, 0%).

Conclusions

Adherence of surgical trials to CONSORT-NPT extension items is much poorer than to the standard CONSORT Statement. Adherence also appears to be superior in general medical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

compared to surgical journals. Raising awareness and conducting qualitative research to identify areas for specific intervention will be important going forward.

For peer review only

ARTICLE SUMMARY

Article focus

- Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials.
- The CONSORT-NPT extension was designed to address these issues but adherence in both medical and surgical journals has not been assessed.
- Our objective was to carry out a systematic review of adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT).

Key messages

- Adherence of surgical trials to CONSORT-NPT extension items is much poorer than to the standard CONSORT Statement. Adherence also appears to be superior in general medical compared to surgical journals.
- Raising awareness and conducting qualitative research to identify areas for specific intervention will be important going forward.

Strengths and limitations of this study

- This study is the first to assess surgical trials reported in both general medical and surgical journals for adherence to the CONSORT-NPT extension.
- However, the final cross-sectional sample was small with only 54 trials. This precluded a detailed statistical analysis.

INTRODUCTION

Randomized controlled trials (RCTs) are designed to determine the association between efficacy of a treatment and clinical outcome. In this regard, they are considered the gold standard of healthcare evidence and the resulting conclusions can significantly affect clinical practice.¹ It is therefore imperative that trials are well designed and correctly executed. However, it is equally important that trials are fully and transparently reported to allow proper critical appraisal by the scientific community.

Key information is often missing from published trials^{2,3} and there may be a correlation between incomplete reporting and poor trial methodology.⁴⁻⁶ Such missing information can include items as crucial as sample size, details of randomisation, blinding and the choice of primary outcome. In response to this problem, the Consolidated Standards of Reporting Trials (CONSORT) statement was launched in 1996 and aimed to provide a checklist of essential items that authors should report when publishing their study.⁷ The CONSORT Statement was updated in 2001 and more recently in 2010 and is now endorsed by more than 600 leading medical journals.^{8,9} Whilst the CONSORT Statement has been credited with improving the reporting standards of RCTs,¹⁰ many recent studies have highlighted remaining deficiencies in both medical¹¹⁻¹⁴ and surgical literature.¹⁵⁻¹⁸

Surgical trials are often considered more difficult to design and execute than pharmacological trials.¹⁹ Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials such as difficulty in blinding patients and outcome assessors, variation in surgical technique and experience of operators. In 2008 an extension to the CONSORT Statement was published providing specific recommendations for the reporting of RCTs of non-pharmacological treatment

1
2
3 (CONSORT-NPT).²⁰ Examples of added items include specifying the eligibility criteria for
4
5 centres performing the intervention and how care providers are allocated to each trial group.
6

7
8 The aim of this study was to analyse the quality of reporting of RCTs in surgery
9
10 published in both medical and surgical journals based on the reporting criteria included in the
11
12 2010 CONSORT Statement and CONSORT-NPT extension.
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

METHODS

Search Strategy

We identified the eight general medical and eight surgical journals with the highest ISI impact factors from the “Medicine, General and Internal” and “Surgery” categories respectively of the 2011 Journal Citation Reports provided by Thomson Reuters.²¹ All 16 journals (see appendix S1) are indexed on PubMed and a search was then conducted to identify reports of RCTs published in these 16 journals. The search (see appendix S2) combined the ‘Cochrane Highly Sensitive Search Strategy for identifying randomized trials’²² with the publication year 2011 and journal name (conducted in March 2012). Additionally, the terms “surgery OR surgical OR surgeon” were added when searching the eight general medical journals to restrict results to RCTs in surgery. The search was conducted independently for each journal. All titles and abstracts retrieved from the search were assessed for eligibility by the authors (MN, MM, DH, WT, FC) such that each record was reviewed independently by at least two authors. Studies in which it was not clear whether the inclusion criteria had been met were reviewed in full text and discrepancies were resolved by consensus. All journals included in our sample are published in English.

Inclusion and exclusion criteria

We defined a randomized trial as a prospective study assessing health-care interventions in human participants who were randomly allocated to study groups. Studies were considered eligible for inclusion if they were: (i) reports of a randomized controlled trial, (ii) published in 2011 (either print or online e-publication during 2011), and (iii) the primary aim of the study was considered an interventional therapy. For the purposes of this study, an interventional therapy was defined as a therapy involving (a) some element of

1
2
3 invasion or trauma to the body and (b) the requirement for operator skill to achieve a
4
5 successful requirement and with the exception of an intervention being used purely to deliver
6
7 a pharmacological treatment (i.e. catheter delivered drug) (see appendix S2). We excluded
8
9 reports where (i) one of the trial arms did not contain an interventional therapy as defined
10
11 above, (ii) a drug was the primary intervention, even in a surgical population (e.g.
12
13 chemotherapy for ovarian cancer) or (iii) the RCT had been previously published and the
14
15 current report was merely a follow-up or subgroup analysis using the same cohort of patients.
16
17
18
19

20 21 **Data extraction**

22
23 We created a modified version of the CONSORT checklist which contained all of the
24
25 2008 CONSORT-NPT checklist items and all of the standard 2010 CONSORT checklist
26
27 items. The resulting checklist had a total of 42 items (see appendix S3). Two authors (DH,
28
29 WT) independently assessed each of the eligible reports against this checklist. Reports were
30
31 also scored by the same authors for trial quality using the extended version of the Linde
32
33 Internal Validity Scale (ELIVS) (see table 3, appendix S2). The ELIVS scoring system used
34
35 in this study was developed from initial work by Jadad et al.²³ and Linde et al.²⁴ It measures
36
37 the following quality domains: treatment allocation, randomisation method, allocation
38
39 concealment, post-randomisation baseline comparison, blinding, handling and reporting of
40
41 withdrawals and intention to treat analysis. Any discrepancies were resolved by consensus.
42
43 Inter-observer analysis was assessed by calculating the Cohen's kappa score (score 0.74
44
45 based on disagreement of 268/2,268 points). Extraction of data from studies was carried out
46
47 in Microsoft Excel (2010, Microsoft Corporation, Redmond, WA, USA) using a pre-piloted
48
49 form that was tested on two randomly selected studies from 2010.
50
51
52
53

54 For each report, we also extracted the following data: the number of authors, the
55
56 continent where the study was conducted, multicentre status, number of study participants and
57
58
59
60

1
2
3 reporting of ethics review and conflict of interest. For each journal included, we obtained the
4
5 ISI 2011 impact factor and whether or not the journal endorsed (e.g. recommended or
6
7 required) the CONSORT Statement and CONSORT-NPT extension (information obtained in
8
9 2012).

14 **Author survey**

15
16 We also emailed the corresponding author for each included report, with five
17
18 questions relating to the CONSORT-NPT extension in April 2013. The questions were: (i)
19
20 Are you currently aware of the 2008 CONSORT-NPT extension? (ii) Were you aware of the
21
22 2008 CONSORT-NPT extension at the time of submission? (iii) Did the journal editorial
23
24 staff mention the CONSORT-NPT extension to you during the editorial process (other than
25
26 the instructions for authors on the journal website)? Did the journal peer reviewers mention
27
28 the CONSORT-NPT extension to you during the review process? (v) Would your choice of
29
30 journal for submission be affected by whether or not the journal mentions the CONSORT-
31
32 NPT extension in their online instructions for authors? Each answer could be reported as
33
34 'yes', 'no' or 'cannot remember/unsure'.
35
36
37
38
39
40

41 **Outcomes and statistical analysis**

42
43 Our primary outcome measure was adherence measured as the proportion of articles
44
45 reporting each individual CONSORT and CONSORT-NPT checklist item. We also compared
46
47 any differences in adherence between reports published in general medical with those
48
49 published in surgical journals. All analyses were performed using STATA statistical software
50
51 version 12.1 (College Station, TX).
52
53
54
55
56
57
58
59
60

RESULTS

Our initial PubMed searches identified 831 possible reports, of which 771 were excluded as ineligible based on the information reported in the title and abstract. Sixty full text articles were retrieved for further assessment of which six were excluded because they were reports of previously published trials. This left 54 RCTs with a combined total of 16,338 patients from 11 journals that met the inclusion criteria (summarised in figure 1).

The baseline characteristics of the included trials are shown in table 1. The medical journals had a tendency toward higher numbers of patients and a larger number of authors as well as a greater proportion of multicentre, higher quality (as measured by the ELIVS scale) trials. The requirement for CONSORT adherence was variable between the medical and surgical journals. Overall, only around half of the articles were published in a journal that required (26/54 studies; 48%) CONSORT adherence (table 1). The percentage of articles published in a journal that mentioned CONSORT in the instructions to peer reviewers (9/54 studies; 27%) was lower.

Table 1. Baseline characteristics of included studies. Abbreviations: COI, conflict of interest; ELIVS, extended linde internal validity scale; IQR, inter-quartile range; ITA, instructions to authors; ITPA, instructions to peer reviewers.

	Overall (n=54)	Medical journals (n=22)	Surgical journals (n=32)
Trial characteristics			
No. of patients, median (IQR)	177 (110-410)	363 (195-757)	129 (71-177)
No. of authors, median (IQR)	9 (6-12)	12 (9-17)	7 (6-11)
Impact factor, median (IQR)	7.5 (4.5-30.0)	33.6 (30.0-53.5)	4.6 (4.4-7.5)
Multicentre trials, no. (%)	28 (52)	20 (91)	8 (25)
Ethics review, no. (%)	54 (100)	22 (100)	32 (100)
COI declared, no. (%)	47 (87)	22 (100)	25 (78)
ELIVS Quality score, mean (SD)	5.1 (1.5)	5.8 (1.4)	4.5 (1.3)
Journal CONSORT endorsement			
CONSORT required in ITA, no. (%)	26 (48)	13 (59)	13 (41)
CONSORT recommended in ITA, no. (%)	28 (52)	9 (41)	19 (59)

CONSORT mentioned in ITPR, no. (%)	9 (27)	6 (27)	3 (10)
------------------------------------	--------	--------	--------

Adherence of trials to the modified CONSORT checklist was variable ranging from 0-100% for each of the individual 42 checklist items (table 2). The highest scoring trials satisfied 36 of 42 items while the lowest scoring trial satisfied only 18 items (median 27, interquartile range 23-31). There were eight items for which there was less than 30% overall compliance (indicated with an asterisk in table 2). Of these eight items, seven were specific to the CONSORT-NPT extension. These seven items related to the following topics: a full description of the care providers, centers and blinding status in the abstract (item 1b; adherence 13%), eligibility criteria for centers performing the interventions (item 4b; adherence 24%), how adherence of care providers with the protocol was assessed or enhanced (item 5c; adherence 13%), how clustering by care providers or centers was addressed as it relates to sample size (item 7a; adherence 6%), how care providers were allocated to each group (item 8b; adherence 17%), how clustering by care providers or centers was addressed as it relates to statistical methods (item 12b; adherence 4%), a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group (item 15b; adherence 0%). The non CONSORT-NPT item with less than 30% adherence related to the presentation of both absolute and relative effect sizes for binary outcomes (item 17b; adherence 28%).

Table 2. Adherence of studies to modified CONSORT-NPT checklist. *Headings in bold are covered within the CONSORT-NPT extension. Non-bold are exclusive to CONSORT 2010 Statement. Further details available in Appendix S3.*

CONSORT Number	Point	Overall adherence, no. (%)	Medical adherence, no. (%)	Surgical adherence, no. (%)
1a	Title and abstract	46 (85)	17 (77)	29 (91)
1b		7 (13)*	7 (32)	0
2a	Background and objectives	54 (100)	22 (100)	32 (100)
2b		54 (100)	22 (100)	32 (100)

3a	Trial design	22 (41)	14 (64)	8 (25)
3b		54 (100)	22 (100)	32 (100)
4a	Participants	54 (100)	22 (100)	32 (100)
4b		13 (24)*	7 (32)	6 (19)
5	Interventions	48 (89)	19 (86)	29 (91)
5a		39 (72)	20 (91)	19 (59)
5b		50 (93)	20 (91)	30 (94)
5c		7 (13)*	6 (27)	1 (3)
6a	Outcomes	48 (89)	22 (100)	26 (81)
6b		54 (100)	22 (100)	32 (100)
7a	Sample size	3 (6)*	2 (9)	1 (3)
7b		52 (96)	22 (100)	30 (94)
8a	Randomisation sequence generation	30 (56)	12 (55)	18 (56)
8b		9 (17)*	2 (9)	7 (22)
9	Allocation concealment mechanism	28 (52)	17 (77)	11 (34)
10	Randomisation implementation	18 (33)	13 (59)	5 (16)
11a	Blinding	29 (54)	16 (73)	13 (41)
11b		30 (56)	16 (73)	14 (44)
12a	Statistical methods	54 (100)	22 (100)	32 (100)
12b		2 (4)*	0	2 (6)
13a	Participant flow	0*	0	0
13b		51 (94)	22 (100)	29 (91)
New	Implementation of intervention	38 (70)	12 (55)	26 (81)
14a	Recruitment	48 (89)	22 (100)	26 (81)
14b		51 (94)	22 (100)	29 (91)
15a	Baseline data	52 (96)	22 (100)	30 (94)
15b		0*	0	0
16	Numbers analysed	52 (96)	22 (100)	30 (94)
17a	Outcomes and estimation	21 (39)	18 (82)	3 (9)
17b		15 (28)*	14 (64)	1 (3)
18	Ancillary analyses	42 (78)	20 (91)	22 (29)
19	Harms	51 (94)	21 (95)	30 (94)
20	Limitations	35 (65)	19 (86)	16 (50)
21	Generalisability	24 (44)	14 (64)	10 (31)
22	Interpretation	51 (94)	22 (100)	29 (91)
23	Registration	49 (91)	22 (100)	27 (84)
24	Protocol	25 (46)	18 (82)	7 (22)
25	Funding	40 (74)	22 (100)	18 (56)

1
2
3
4
5 We did not compare the different adherence rates in a statistically formal way
6
7 between the trials published in general medical and surgical journals as originally planned
8
9 owing to the small sample size and the large number of hypotheses that could potentially be
10
11 tested (all 42 checklist items). General medical journals tended to report better adherence to
12
13 checklist items than surgical journals.
14

15
16 We contacted the lead author for each of the 54 reports to ask about their awareness
17
18 of CONSORT-NPT. Only 17 authors replied (31% response rate) and so we were therefore
19
20 not able to perform formal quantitative analysis on the survey results. Based on the replies we
21
22 received, approximately a third of respondents were aware of CONSORT-NPT at the time of
23
24 submission, while two thirds are aware of its existence now (table 3). Given the time lapse
25
26 between manuscript submission and our short survey, about a quarter of respondents were
27
28 unable to remember whether journal editors and peer reviewers had mentioned CONSORT-
29
30 NPT during the review process. Finally, a third of respondents agreed that their choice of
31
32 journal for submission would be affected by whether or not CONSORT-NPT was mentioned
33
34 in the instructions for authors section of the journal (we did not ascertain the direction of this
35
36 preference).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Results from survey of corresponding authors. Abbreviations: NPT, non-pharmacological treatment CONSORT extension statement.

Question no.	Topic	Yes	No	Can't remember / Not sure
1	Currently aware of NPT	11 (65%)	5 (35%)	0
2	Aware of NPT at submission	6 (35%)	10 (65%)	0
3	NPT mentioned by editorial staff	2 (12%)	10 (59%)	5 (29%)
4	NPT mentioned by peer-reviewers	1 (6%)	11 (71%)	4 (24%)
5	NPT endorsement by journal would affect submission choice	5 (29%)	10 (65%)	1 (6%)

DISCUSSION

Summary of main findings

In this study, we included 54 reports of surgical RCTs published in 2011 from a cross sectional sample of 11 medical and surgical journals. We assessed these reports for their adherence to a combined CONSORT and CONSORT-NPT checklist with two main findings. Firstly, reporting adherence of surgical RCTs to the CONSORT-NPT extension was much poorer than adherence to the main CONSORT checklist. Secondly, general medical journals were broadly superior in their NPT reporting as compared to surgical journals. To our knowledge this is the first study to demonstrate this difference between journal types for the CONSORT-NPT extension and one of only a few studies to document NPT adherence.

Comparison with the literature

The findings from our study are in agreement with the existing literature on CONSORT adherence. A recent systematic review of 53 studies found that reporting has remained sub-optimal despite the CONSORT Statement having been active in various iterations since 1996.²⁵ However, the authors suggest that journal endorsement does appear to have had a positive impact on adherence. One review that included a comparison between surgical RCTs published in both medical and surgical journals also found that adherence to CONSORT items was significantly superior in medical journals.¹⁶ Both of these articles assessed adherence only to the standard CONSORT Statement. A more recent study that assessed adherence specifically to the CONSORT-NPT extension checklist both before (2004) and after (2010) the checklist was launched found little improvement in NPT specific items (although these have had less time for absorption by the community than the standard

1
2
3 CONSORT Statement).¹⁷ These were reported in less than 50% of trials during 2010. The
4
5 adherence rates in our study for similar NPT items were even lower.
6
7

8 9 10 **Limitations**

11
12 Our study has several limitations. First, we only included studies published in high
13
14 impact English language journals indexed in PubMed in 2011. In combination with our strict
15
16 inclusion criteria on what constituted a surgical intervention, this led to a small sample of
17
18 only 54 RCTs. We were consequently unable to perform detailed statistical analysis on
19
20 individual checklist items. The decision to limit the cross-sectional sample to one year was
21
22 made on pragmatic grounds owing to the very lengthy process of scoring the RCTs against
23
24 the checklist items. It was also for this reason that we restricted the number of journals we
25
26 searched to the top eight impact factor journals within each specialty.
27
28

29
30 A second limitation pertains to the cross-sectional nature of our study. We are unable
31
32 to suggest whether any progress is being made in adherence to the NPT extension. As
33
34 previously described, an interrupted before-after study found only moderate improvement
35
36 between 2004 and 2010.¹⁷ Our author survey suggested that there had been an increase in the
37
38 proportion of authors who were aware of the existence of the CONSORT-NPT extension
39
40 between the time of submission and now. Whether this translates to improved adherence at
41
42 the current time is unknown. A third limitation includes the fact that we did not assess study
43
44 protocols for adherence to CONSORT criteria. Some authors may have included additional
45
46 study details within the protocol.
47
48

49
50 A final limitation concerns the author survey. We were restricted in our ability to
51
52 analyse this data by the poor response rate and the significant time lag between submission of
53
54 the RCTs (circa 2010) and distribution of the survey to corresponding authors in 2013.
55
56
57
58
59
60

Implications for authors and journals

The CONSORT-NPT items with the poorest adherence were predominantly related to details on the implementation of the intervention, the providers (surgeons) and the centres. The CONSORT-NPT extension was specifically created to encourage reporting of these intervention specific items given their importance in generalising a trial intervention to non-trial populations. As an example, two early symptomatic carotid surgery trials, NASCET and ACAS,^{26, 27} both had restrictive criteria for selecting which surgeons and centres were permitted to perform the intervention. Consequently, one large national cohort study that followed on from these trials did not see as large an improvement in patient outcomes.²⁸ The study pointed out that less than 4% of all US hospitals providing carotid endarterectomy were included in NASCET and indeed that Medicare patients treated at trial hospitals had a lower risk of dying than at other hospitals.

We might anecdotally expect CONSORT-NPT items to be more vigorously enforced by surgical journals. This is on the basis that surgeons (who would likely form a greater component of the journal's editorial board and peer reviewers) would be more familiar with the multiple elements of the intervention and the importance of these elements in their own practice. Naturally therefore, they might be keener to see these reported more thoroughly in manuscripts reporting RCTs. Our results appear to suggest the opposite in that general medical journals displayed superior NPT adherence. It is difficult to ascertain whether this finding is confounded by the much larger impact factor of the general medical journals in our sample and the potential for a self-fulfilling prophecy (i.e. better reported trials opt preferentially to try and publish in the high impact medical journals rather than such RCTs being well reported as a prime result of enforcement by the medical journal). Overall, the wealth of potential confounders makes it difficult to conclude why medical journals displayed superior adherence.

1
2
3 The literature on CONSORT adherence failures is extensive and is developing
4 similarly for the CONSORT-NPT extension.²⁵ Now that the problem has been well
5 documented, the focus will likely shift towards identifying actionable areas for intervention.
6
7 In the first instance, we suggest that qualitative interviews and focus groups with
8 stakeholders at surgical trials departments will be important. Identifying the precise barriers
9 to adherence will better inform the community on how best to improve reporting and where
10 the greatest impact can be had. For example, does the problem lie with restrictive word
11 counts, lack of time, lack of enforcement or simply just lack of awareness? How far would
12 journals be prepared to go with enforcement? Would this be a viable option for smaller
13 impact journals, perhaps fearful of driving authors away by enforcing reporting guidelines
14 too rigidly?
15
16
17
18
19
20
21
22
23
24
25
26

27 These are all important questions that could be further elucidated by qualitative
28 research in this field. New guidance on surgical RCT methodology²⁹ and calls for greater
29 investment in surgical research³⁰ should be combined with greater awareness of the
30 CONSORT-NPT extension. Reporting standards, like trial design are not static but need to
31 adapt to the changing research landscape. CONSORT therefore needs to respond to proposals
32 for new reporting standards such as those proposed by the IDEAL Collaboration²⁹ in future
33 NPT extensions. Notably, the All Trials movement pushing for transparency of
34 pharmaceutical trials has garnered much attention from the public and press over recent
35 months.³¹ This momentum has added weight to the growing call for thorough reporting to be
36 considered a core duty of clinician researchers rather than just a desirable trait.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Conclusion**

53
54 The findings from this cross sectional review of surgical trials suggest that adherence
55 to CONSORT-NPT extension items is much poorer than to the standard CONSORT
56
57
58
59
60

1
2
3 Statement. Adherence also appears to be superior in general medical compared to surgical
4
5 journals. A combination of more qualitative research to identify areas for specific
6
7 intervention and a continuing effort to raise awareness of the CONSORT-NPT extension
8
9
10 among stakeholders will be important going forward.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ACKNOWLEDGEMENTS

None.

COMPETING INTERESTS

SH, Centre for Statistics in Medicine, is a member of the CONSORT group. PM is the Chair of the IDEAL Collaboration.

FUNDING

No funding was received from any source for any part of this work.

DATA SHARING STATEMENT

Electronic data collection sheets are available on request.

CONTRIBUTORSHIP

MN, CFC, MM conceived of the study. MN, CFC, MM, PM, SH were involved in the design. MN, DH, WT, CFC, MM independently identified studies for inclusion. DH and WT collected data from includable studies. MN analysed the data and wrote the first draft of the report. All authors contributed to subsequent drafts and approved the final version of the manuscript.

References

1. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. *J Clin Epidemiol*. 1999; **52**(6): 487-97.
2. Dickinson K, Bunn F, Wentz R, et al. Size and quality of randomised controlled trials in head injury: review of published studies. *BMJ*. 2000; **320**(7245): 1308-11.
3. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. *BMJ*. 1998; **317**(7167): 1181-4.
4. Huwiler-Muntener K, Juni P, Junker C, et al. Quality of reporting of randomized trials as a measure of methodologic quality. *JAMA*. 2002; **287**(21): 2801-4.
5. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ*. 2001; **323**(7303): 42-6.
6. Montori VM, Wang YG, Alonso-Coello P, et al. Systematic evaluation of the quality of randomized controlled trials in diabetes. *Diabetes Care*. 2006; **29**(8): 1833-8.
7. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA*. 1996; **276**(8): 637-9.
8. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010; **340**: c869.
9. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet*. 2001; **357**(9263): 1191-4.
10. Turner L, Shamseer L, Altman DG, et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. *Syst Rev*. 2012; **1**: 60.
11. Devereaux PJ, Manns BJ, Ghali WA, et al. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. *Control Clin Trials*. 2002; **23**(4): 380-8.

12. Haidich AB, Birtsou C, Dardavessis T, et al. The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. *J Clin Epidemiol*. 2011; **64**(2): 124-35.
13. Mills EJ, Wu P, Gagnier J, et al. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. *Contemp Clin Trials*. 2005; **26**(4): 480-7.
14. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA*. 2001; **285**(15): 1992-5.
15. Agha R, Cooper D, Muir G. The reporting quality of randomised controlled trials in surgery: a systematic review. *Int J Surg*. 2007; **5**(6): 413-22.
16. Balasubramanian SP, Wiener M, Alshameeri Z, et al. Standards of reporting of randomized controlled trials in general surgery: can we do better? *Ann Surg*. 2006; **244**(5): 663-7.
17. Gray R, Sullivan M, Altman DG, et al. Adherence of trials of operative intervention to the CONSORT statement extension for non-pharmacological treatments: a comparative before and after study. *Ann R Coll Surg Engl*. 2012; **94**(6): 388-94.
18. Sinha S, Ashby E, Jayaram R, et al. Quality of reporting in randomized trials published in high-quality surgical journals. *J Am Coll Surg*. 2009; **209**(5): 565-71 e1.
19. McCulloch P, Taylor I, Sasako M, et al. Randomised trials in surgery: problems and possible solutions. *BMJ*. 2002; **324**(7351): 1448-51.
20. Boutron I, Moher D, Altman DG, et al. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med*. 2008; **148**(4): 295-309.
21. Thomson-Reuters. ISI Web of Knowledge. 2012 [cited 18 September 2012]; Available from: <http://wok.mimas.ac.uk/>
22. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration; 2011.
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996; **17**(1): 1-12.
24. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. *BMJ*. 1996; **313**(7052): 253-8.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *Cochrane Database Syst Rev.* 2012; **11**: MR000030.
26. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med.* 1991; **325**(7): 445-53.
27. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA.* 1995; **273**(18): 1421-8.
28. Wennberg DE, Lucas FL, Birkmeyer JD, et al. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. *JAMA.* 1998; **279**(16): 1278-81.
29. Cook JA, McCulloch P, Blazeby JM, et al. IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage. *BMJ.* 2013; **346**: f2820.
30. McCulloch P. How to improve surgical research. *BMJ.* 2011; **343**: d4121.
31. Brown T. It's Time for AllTrials Registered and Reported. *Cochrane Database Syst Rev.* 2013; **5**: ED000057.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Poor adherence of randomised trials in surgery to CONSORT guidelines
for non-pharmacologic treatments (NPT): a cross-sectional study systematic
review**

Dr Myura Nagendran¹

Daniel Harding²

Wendy Teo³

Dr Christian Camm⁴

Dr Mahiben Maruthappu⁵

Mr Peter McCulloch⁶

Dr Sally Hopewell^{7,8}

1. Green Templeton College, University of Oxford, Oxford, UK
2. Magdalen College, University of Oxford, Oxford, UK
3. Keble College, University of Oxford, Oxford, UK
4. New College, University of Oxford, Oxford, UK
5. Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, USA
6. Nuffield Department of Surgery, John Radcliffe Hospital, University of Oxford, Oxford, UK
7. Centre for Statistics in Medicine, University of Oxford, Oxford, UK
8. INSERM U738 Paris, France; Centre d'Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France

Corresponding author:

Dr Myura Nagendran

Green Templeton College,

University of Oxford

Woodstock Road, Oxford. OX2 6HG, UK

E: myura.nagendran@imperial.ac.uk

T: +44 791 255 6717

F: +44 1865 274 796

Keywords: Checklist/standards, Publishing/standards, Randomized Controlled Trials, Reference Standards

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| Word count: 2,9612,955

For peer review only

ABSTRACT

Objective

To systematically assess adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT). Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials. The CONSORT-NPT extension was designed to address these issues but adherence in both medical and surgical journals has not been assessed.

Design

Cross-sectional study. Systematic review.

Sample

We identified eight general medical and eight surgical journals, indexed in PubMed and published in 2011, with the highest impact factors in their respective categories.

Main outcomes

Adherence to CONSORT Statement and CONSORT-NPT extension items.

Results

We identified 54 surgical trials (22 published in medical journals and 32 in surgical journals). There were eight items for which there was less than 30% overall compliance (seven were specific to the CONSORT-NPT extension). These seven items related to: a full description of the care providers, centers and blinding status in the abstract (n=7/54, 13%), eligibility criteria for centers performing the interventions (n=13/54, 24%), how adherence of care providers with the protocol was assessed or enhanced (n=7/54, 13%), how clustering by care providers or centers was addressed as it relates to sample size (n=3/54, 6%), how care providers were allocated to each group (n=9/54, 17%), how clustering by care providers or centers was addressed as it relates to statistical methods (n=2/54, 4%), a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group (n=0/54, 0%).

Conclusions

Adherence of surgical trials to CONSORT-NPT extension items is much poorer than to the standard CONSORT Statement. Adherence also appears to be superior in general medical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

compared to surgical journals. Raising awareness and conducting qualitative research to identify areas for specific intervention will be important going forward.

For peer review only

ARTICLE SUMMARY

Article focus

- Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials.
- The CONSORT-NPT extension was designed to address these issues but adherence in both medical and surgical journals has not been assessed.
- Our objective was to carry out a systematic review of adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacologic treatments (NPT).

Key messages

- Adherence of surgical trials to CONSORT-NPT extension items is much poorer than to the standard CONSORT Statement. Adherence also appears to be superior in general medical compared to surgical journals.
- Raising awareness and conducting qualitative research to identify areas for specific intervention will be important going forward.

Strengths and limitations of this study

- This study is the first to assess surgical trials reported in both general medical and surgical journals for adherence to the CONSORT-NPT extension.
- However, the final cross-sectional sample was small with only 54 trials. This precluded a detailed statistical analysis.

INTRODUCTION

Randomized controlled trials (RCTs) are designed to determine the association between efficacy of a treatment and clinical outcome. In this regard, they are considered the gold standard of healthcare evidence and the resulting conclusions can significantly affect clinical practice.¹ It is therefore imperative that trials are well designed and correctly executed. However, it is equally important that trials are fully and transparently reported to allow proper critical appraisal by the scientific community.

Key information is often missing from published trials^{2,3} and there may be a correlation between incomplete reporting and poor trial methodology.⁴⁻⁶ Such missing information can include items as crucial as sample size, details of randomisation, blinding and the choice of primary outcome. In response to this problem, the Consolidated Standards of Reporting Trials (CONSORT) statement was launched in 1996 and aimed to provide a checklist of essential items that authors should report when publishing their study.⁷ The CONSORT Statement was updated in 2001 and more recently in 2010 and is now endorsed by more than 600 leading medical journals.^{8,9} Whilst the CONSORT Statement has been credited with improving the reporting standards of RCTs,¹⁰ many recent studies have highlighted remaining deficiencies in both medical¹¹⁻¹⁴ and surgical literature.¹⁵⁻¹⁸

Surgical trials are often considered more difficult to design and execute than pharmacological trials.¹⁹ Furthermore, the original CONSORT Statement does not address some aspects that are vital to the transparent reporting of surgical trials such as difficulty in blinding patients and outcome assessors, variation in surgical technique and experience of operators. In 2008 an extension to the CONSORT Statement was published providing specific recommendations for the reporting of RCTs of non-pharmacological treatment

1
2
3 (CONSORT-NPT).²⁰ Examples of added items include specifying the eligibility criteria for
4
5 centres performing the intervention and how care providers are allocated to each trial group.
6
7

8 The aim of this study was to analyse the quality of reporting of RCTs in surgery
9
10 published in both medical and surgical journals based on the reporting criteria included in the
11
12 2010 CONSORT Statement and CONSORT-NPT extension.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search Strategy

We identified the eight general medical and eight surgical journals with the highest ISI impact factors from the “Medicine, General and Internal” and “Surgery” categories respectively of the 2011 Journal Citation Reports provided by Thomson Reuters.²¹ All 16 journals (see appendix S1) are indexed on PubMed and a search was then conducted to identify reports of RCTs published in these 16 journals. The search (see appendix S2) combined the ‘Cochrane Highly Sensitive Search Strategy for identifying randomized trials’²² with the publication year 2011 and journal name (conducted in March 2012). Additionally, the terms “surgery OR surgical OR surgeon” were added when searching the eight general medical journals to restrict results to RCTs in surgery. The search was conducted independently for each journal. All titles and abstracts retrieved from the search were assessed for eligibility by the authors (MN, MM, DH, WT, FC) such that each record was reviewed independently by at least two authors. Studies in which it was not clear whether the inclusion criteria had been met were reviewed in full text and discrepancies were resolved by consensus. All journals included in our sample are published in English.

Inclusion and exclusion criteria

We defined a randomized trial as a prospective study assessing health-care interventions in human participants who were randomly allocated to study groups. Studies were considered eligible for inclusion if they were: (i) reports of a randomized controlled trial, (ii) published in 2011 (either print or online e-publication during 2011), and (iii) the primary aim of the study was considered an interventional therapy. For the purposes of this study, an interventional therapy was defined as a therapy involving (a) some element of

1
2
3 invasion or trauma to the body and (b) the requirement for operator skill to achieve a
4
5 successful requirement and with the exception of an intervention being used purely to deliver
6
7 a pharmacological treatment (i.e. catheter delivered drug) (see appendix S2). We excluded
8
9 reports where (i) one of the trial arms did not contain an interventional therapy as defined
10
11 above, (ii) a drug was the primary intervention, even in a surgical population (e.g.
12
13 chemotherapy for ovarian cancer) or (iii) the RCT had been previously published and the
14
15 current report was merely a follow-up or subgroup analysis using the same cohort of patients.
16
17
18
19
20

21 **Data extraction**

22
23 We created a modified version of the CONSORT checklist which contained all of the
24
25 2008 CONSORT-NPT checklist items and all of the standard 2010 CONSORT checklist
26
27 items. The resulting checklist had a total of 42 items (see appendix S3). Two authors (DH,
28
29 WT) independently assessed each of the eligible reports against this checklist. Reports were
30
31 also scored by the same authors for trial quality using the extended version of the Linde
32
33 Internal Validity Scale (ELIVS) (see table 3, appendix S2). The ELIVS scoring system used
34
35 in this study was developed from initial work by Jadad et al.²³ and Linde et al.²⁴ It measures
36
37 the following quality domains: treatment allocation, randomisation method, allocation
38
39 concealment, post-randomisation baseline comparison, blinding, handling and reporting of
40
41 withdrawals and intention to treat analysis. Any discrepancies were resolved by consensus.
42
43
44

45 Inter-observer analysis was assessed by calculating the Cohen's kappa score (score 0.74
46
47 based on disagreement of 268/2,268 points). Extraction of data from studies was carried out
48
49 in Microsoft Excel (2010, Microsoft Corporation, Redmond, WA, USA) using a pre-piloted
50
51 form that was tested on two randomly selected studies from 2010.
52
53

54 For each report, we also extracted the following data: the number of authors, the
55
56 continent where the study was conducted, multicentre status, number of study participants and
57
58
59
60

1
2
3 reporting of ethics review and conflict of interest. For each journal included, we obtained the
4
5 ISI 2011 impact factor and whether or not the journal endorsed (e.g. recommended or
6
7 required) the CONSORT Statement and CONSORT-NPT extension (information obtained in
8
9 2012).

14 **Author survey**

15
16 We also emailed the corresponding author for each included report, with five
17
18 questions relating to the CONSORT-NPT extension in April 2013. The questions were: (i)
19
20 Are you currently aware of the 2008 CONSORT-NPT extension? (ii) Were you aware of the
21
22 2008 CONSORT-NPT extension at the time of submission? (iii) Did the journal editorial
23
24 staff mention the CONSORT-NPT extension to you during the editorial process (other than
25
26 the instructions for authors on the journal website)? Did the journal peer reviewers mention
27
28 the CONSORT-NPT extension to you during the review process? (v) Would your choice of
29
30 journal for submission be affected by whether or not the journal mentions the CONSORT-
31
32 NPT extension in their online instructions for authors? Each answer could be reported as
33
34 'yes', 'no' or 'cannot remember/unsure'.
35
36
37
38
39
40

41 **Outcomes and statistical analysis**

42
43 Our primary outcome measure was adherence measured as the proportion of articles
44
45 reporting each individual CONSORT and CONSORT-NPT checklist item. We also compared
46
47 any differences in adherence between reports published in general medical with those
48
49 published in surgical journals. All analyses were performed using STATA statistical software
50
51 version 12.1 (College Station, TX).
52
53
54
55
56
57
58
59
60

RESULTS

Our initial PubMed searches identified 831 possible reports, of which 771 were excluded as ineligible based on the information reported in the title and abstract. Sixty full text articles were retrieved for further assessment of which six were excluded because they were reports of previously published trials. This left 54 RCTs with a combined total of 16,338 patients from 11 journals that met the inclusion criteria (summarised in figure 1).

The baseline characteristics of the included trials are shown in table 1. The medical journals had a tendency toward higher numbers of patients and a larger number of authors as well as a greater proportion of multicentre, higher quality (as measured by the ELIVS scale) trials. The requirement for CONSORT adherence was variable between the medical and surgical journals. Overall, only around half of the articles were published in a journal that required (26/54 studies; 48%) CONSORT adherence (table 1). The percentage of articles published in a journal that mentioned CONSORT in the instructions to peer reviewers (9/54 studies; 27%) was lower.

Table 1. Baseline characteristics of included studies. Abbreviations: COI, conflict of interest; ELIVS, extended linde internal validity scale; IQR, inter-quartile range; ITA, instructions to authors; ITPA, instructions to peer reviewers.

	Overall (n=54)	Medical journals (n=22)	Surgical journals (n=32)
Trial characteristics			
No. of patients, median (IQR)	177 (110-410)	363 (195-757)	129 (71-177)
No. of authors, median (IQR)	9 (6-12)	12 (9-17)	7 (6-11)
Impact factor, median (IQR)	7.5 (4.5-30.0)	33.6 (30.0-53.5)	4.6 (4.4-7.5)
Multicentre trials, no. (%)	28 (52)	20 (91)	8 (25)
Ethics review, no. (%)	54 (100)	22 (100)	32 (100)
COI declared, no. (%)	47 (87)	22 (100)	25 (78)
ELIVS Quality score, mean (SD)	5.1 (1.5)	5.8 (1.4)	4.5 (1.3)
Journal CONSORT endorsement			
CONSORT required in ITA, no. (%)	26 (48)	13 (59)	13 (41)
CONSORT recommended in ITA, no. (%)	28 (52)	9 (41)	19 (59)

CONSORT mentioned in ITPR, no. (%)	9 (27)	6 (27)	3 (10)
------------------------------------	--------	--------	--------

Adherence of trials to the modified CONSORT checklist was variable ranging from 0-100% for each of the individual 42 checklist items (table 2). The highest scoring trials satisfied 36 of 42 items while the lowest scoring trial satisfied only 18 items (median 27, interquartile range 23-31). There were eight items for which there was less than 30% overall compliance (indicated with an asterisk in table 2). Of these eight items, seven were specific to the CONSORT-NPT extension. These seven items related to the following topics: a full description of the care providers, centers and blinding status in the abstract (item 1b; adherence 13%), eligibility criteria for centers performing the interventions (item 4b; adherence 24%), how adherence of care providers with the protocol was assessed or enhanced (item 5c; adherence 13%), how clustering by care providers or centers was addressed as it relates to sample size (item 7a; adherence 6%), how care providers were allocated to each group (item 8b; adherence 17%), how clustering by care providers or centers was addressed as it relates to statistical methods (item 12b; adherence 4%), a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group (item 15b; adherence 0%). The non CONSORT-NPT item with less than 30% adherence related to the presentation of both absolute and relative effect sizes for binary outcomes (item 17b; adherence 28%).

Table 2. Adherence of studies to modified CONSORT-NPT checklist. *Headings in bold are covered within the CONSORT-NPT extension. Non-bold are exclusive to CONSORT 2010 Statement. Further details available in Appendix S3.*

CONSORT Number	Point	Overall adherence, no. (%)	Medical adherence, no. (%)	Surgical adherence, no. (%)
1a	Title and abstract	46 (85)	17 (77)	29 (91)
1b		7 (13)*	7 (32)	0
2a	Background and objectives	54 (100)	22 (100)	32 (100)
2b		54 (100)	22 (100)	32 (100)

3a	Trial design	22 (41)	14 (64)	8 (25)
3b		54 (100)	22 (100)	32 (100)
4a	Participants	54 (100)	22 (100)	32 (100)
4b		13 (24)*	7 (32)	6 (19)
5	Interventions	48 (89)	19 (86)	29 (91)
5a		39 (72)	20 (91)	19 (59)
5b		50 (93)	20 (91)	30 (94)
5c		7 (13)*	6 (27)	1 (3)
6a	Outcomes	48 (89)	22 (100)	26 (81)
6b		54 (100)	22 (100)	32 (100)
7a	Sample size	3 (6)*	2 (9)	1 (3)
7b		52 (96)	22 (100)	30 (94)
8a	Randomisation sequence generation	30 (56)	12 (55)	18 (56)
8b		9 (17)*	2 (9)	7 (22)
9	Allocation concealment mechanism	28 (52)	17 (77)	11 (34)
10	Randomisation implementation	18 (33)	13 (59)	5 (16)
11a	Blinding	29 (54)	16 (73)	13 (41)
11b		30 (56)	16 (73)	14 (44)
12a	Statistical methods	54 (100)	22 (100)	32 (100)
12b		2 (4)*	0	2 (6)
13a	Participant flow	0*	0	0
13b		51 (94)	22 (100)	29 (91)
New	Implementation of intervention	38 (70)	12 (55)	26 (81)
14a	Recruitment	48 (89)	22 (100)	26 (81)
14b		51 (94)	22 (100)	29 (91)
15a	Baseline data	52 (96)	22 (100)	30 (94)
15b		0*	0	0
16	Numbers analysed	52 (96)	22 (100)	30 (94)
17a	Outcomes and estimation	21 (39)	18 (82)	3 (9)
17b		15 (28)*	14 (64)	1 (3)
18	Ancillary analyses	42 (78)	20 (91)	22 (29)
19	Harms	51 (94)	21 (95)	30 (94)
20	Limitations	35 (65)	19 (86)	16 (50)
21	Generalisability	24 (44)	14 (64)	10 (31)
22	Interpretation	51 (94)	22 (100)	29 (91)
23	Registration	49 (91)	22 (100)	27 (84)
24	Protocol	25 (46)	18 (82)	7 (22)
25	Funding	40 (74)	22 (100)	18 (56)

1
2
3
4
5 We did not ~~statistically~~ compare the different adherence rates in a statistically formal
6 way between the trials published in general medical and surgical journals as originally
7 planned owing to the small sample size and the large number of hypotheses that could
8 potentially be tested (all 42 checklist items). ~~However, in comparing the percentage~~
9 ~~adherence rates between the two journal groups,~~ general medical journals tended to report
10 better adherence to checklist items than surgical journals. ~~typically generated superior~~
11 ~~adherence. There were three exceptions where surgical journal adherence was more than 10%~~
12 ~~superior to trials published in medical journals (item 1a, identification as a randomised trial in~~
13 ~~the title; item 8b, allocation of care providers to each group; item “New”, implementation of~~
14 ~~intervention as it was implemented.~~

15
16
17
18
19
20
21
22
23
24
25
26
27 We contacted the lead author for each of the 54 reports to ask about their awareness
28 of CONSORT-NPT. Only 17 authors replied (31% response rate) and so we were therefore
29 not able to perform formal quantitative analysis on the survey results. Based on the replies we
30 received, approximately a third of respondents were aware of CONSORT-NPT at the time of
31 submission, while two thirds are aware of its existence now (table 3). Given the time lapse
32 between manuscript submission and our short survey, about a quarter of respondents were
33 unable to remember whether journal editors and peer reviewers had mentioned CONSORT-
34 NPT during the review process. Finally, a third of respondents agreed that their choice of
35 journal for submission would be affected by whether or not CONSORT-NPT was mentioned
36 in the instructions for authors section of the journal (we did not ascertain the direction of this
37 preference).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Results from survey of corresponding authors. Abbreviations: NPT, non-pharmacological treatment CONSORT extension statement.

Question no.	Topic	Yes	No	Can't remember / Not sure
1	Currently aware of NPT	11 (65%)	5 (35%)	0
2	Aware of NPT at submission	6 (35%)	10 (65%)	0
3	NPT mentioned by editorial staff	2 (12%)	10 (59%)	5 (29%)
4	NPT mentioned by peer-reviewers	1 (6%)	11 (71%)	4 (24%)
5	NPT endorsement by journal would affect submission choice	5 (29%)	10 (65%)	1 (6%)

DISCUSSION

Summary of main findings

In this study, we included 54 reports of surgical RCTs published in 2011 from a cross sectional sample of 11 medical and surgical journals. We assessed these reports for their adherence to a combined CONSORT and CONSORT-NPT checklist with two main findings. Firstly, reporting adherence of surgical RCTs to the CONSORT-NPT extension was much poorer than adherence to the main CONSORT checklist. Secondly, general medical journals were broadly superior in their NPT reporting as compared to surgical journals. To our knowledge this is the first study to demonstrate this difference between journal types for the CONSORT-NPT extension and one of only a few studies to document NPT adherence.

Comparison with the literature

The findings from our study are in agreement with the existing literature on CONSORT adherence. A recent systematic review of 53 studies found that reporting has remained sub-optimal despite the CONSORT Statement having been active in various iterations since 1996.²⁵ However, the authors suggest that journal endorsement does appear to have had a positive impact on adherence. One review that included a comparison between surgical RCTs published in both medical and surgical journals also found that adherence to CONSORT items was significantly superior in medical journals.¹⁶ Both of these articles assessed adherence only to the standard CONSORT Statement. A more recent study that assessed adherence specifically to the CONSORT-NPT extension checklist both before (2004) and after (2010) the checklist was launched found little improvement in NPT specific items (although these have had less time for absorption by the community than the standard

1
2
3 CONSORT Statement).¹⁷ These were reported in less than 50% of trials during 2010. The
4
5 adherence rates in our study for similar NPT items were even lower.
6
7

8 9 10 **Limitations**

11
12 Our study has several limitations. First, we only included studies published in high
13
14 impact English language journals indexed in PubMed in 2011. In combination with our strict
15
16 inclusion criteria on what constituted a surgical intervention, this led to a small sample of
17
18 only 54 RCTs. We were consequently unable to perform detailed statistical analysis on
19
20 individual checklist items. The decision to limit the cross-sectional sample to one year was
21
22 made on pragmatic grounds owing to the very lengthy process of scoring the RCTs against
23
24 the checklist items. It was also for this reason that we restricted the number of journals we
25
26 searched to the top eight impact factor journals within each specialty.
27
28

29
30 A second limitation pertains to the cross-sectional nature of our study. We are unable
31
32 to suggest whether any progress is being made in adherence to the NPT extension. As
33
34 previously described, an interrupted before-after study found only moderate improvement
35
36 between 2004 and 2010.¹⁷ Our author survey suggested that there had been an increase in the
37
38 proportion of authors who were aware of the existence of the CONSORT-NPT extension
39
40 between the time of submission and now. Whether this translates to improved adherence at
41
42 the current time is unknown. A third limitation includes the fact that we did not assess study
43
44 protocols for adherence to CONSORT criteria. Some authors may have included additional
45
46 study details within the protocol.
47
48

49
50 A final limitation concerns the author survey. We were restricted in our ability to
51
52 analyse this data by the poor response rate and the significant time lag between submission of
53
54 the RCTs (circa 2010) and distribution of the survey to corresponding authors in 2013.
55
56
57
58
59
60

Implications for authors and journals

The CONSORT-NPT items with the poorest adherence were predominantly related to details on the implementation of the intervention, the providers (surgeons) and the centres. The CONSORT-NPT extension was specifically created to encourage reporting of these intervention specific items given their importance in generalising a trial intervention to non-trial populations. As an example, two early symptomatic carotid surgery trials, NASCET and ACAS,^{26, 27} both had restrictive criteria for selecting which surgeons and centres were permitted to perform the intervention. Consequently, one large national cohort study that followed on from these trials did not see as large an improvement in patient outcomes.²⁸ The study pointed out that less than 4% of all US hospitals providing carotid endarterectomy were included in NASCET and indeed that Medicare patients treated at trial hospitals had a lower risk of dying than at other hospitals.

We might anecdotally expect CONSORT-NPT items to be more vigorously enforced by surgical journals. This is on the basis that surgeons (who would likely form a greater component of the journal's editorial board and peer reviewers) would be more familiar with the multiple elements of the intervention and the importance of these elements in their own practice. Naturally therefore, they might be keener to see these reported more thoroughly in manuscripts reporting RCTs. Our results appear to suggest the opposite in that general medical journals displayed superior NPT adherence. It is difficult to ascertain whether this finding is confounded by the much larger impact factor of the general medical journals in our sample and the potential for a self-fulfilling prophecy (i.e. better reported trials opt preferentially to try and publish in the high impact medical journals rather than such RCTs being well reported as a prime result of enforcement by the medical journal). Overall, the wealth of potential confounders makes it difficult to conclude why medical journals displayed superior adherence.

1
2
3 The literature on CONSORT adherence failures is extensive and is developing
4
5 similarly for the CONSORT-NPT extension.²⁵ Now that the problem has been well
6
7 documented, the focus will likely shift towards identifying actionable areas for intervention.
8
9 In the first instance, we suggest that qualitative interviews and focus groups with
10
11 stakeholders at surgical trials departments will be important. Identifying the precise barriers
12
13 to adherence will better inform the community on how best to improve reporting and where
14
15 the greatest impact can be had. For example, does the problem lie with restrictive word
16
17 counts, lack of time, lack of enforcement or simply just lack of awareness? How far would
18
19 journals be prepared to go with enforcement? Would this be a viable option for smaller
20
21 impact journals, perhaps fearful of driving authors away by enforcing reporting guidelines
22
23 too rigidly?
24
25

26
27 These are all important questions that could be further elucidated by qualitative
28
29 research in this field. New guidance on surgical RCT methodology²⁹ and calls for greater
30
31 investment in surgical research³⁰ should be combined with greater awareness of the
32
33 CONSORT-NPT extension. Reporting standards, like trial design are not static but need to
34
35 adapt to the changing research landscape. CONSORT therefore needs to respond to proposals
36
37 for new reporting standards such as those proposed by the IDEAL Collaboration²⁹ in future
38
39 NPT extensions. Notably, the All Trials movement pushing for transparency of
40
41 pharmaceutical trials has garnered much attention from the public and press over recent
42
43 months.³¹ This momentum has added weight to the growing call for thorough reporting to be
44
45 considered a core duty of clinician researchers rather than just a desirable trait.
46
47
48
49
50

51 **Conclusion**

52
53 The findings from this cross sectional review of surgical trials suggest that adherence
54
55 to CONSORT-NPT extension items is much poorer than to the standard CONSORT
56
57
58
59
60

1
2
3 Statement. Adherence also appears to be superior in general medical compared to surgical
4
5 journals. A combination of more qualitative research to identify areas for specific
6
7 intervention and a continuing effort to raise awareness of the CONSORT-NPT extension
8
9
10 among stakeholders will be important going forward.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ACKNOWLEDGEMENTS

None.

COMPETING INTERESTS

SH, Centre for Statistics in Medicine, is a member of the CONSORT group. PM is the Chair of the IDEAL Collaboration.

FUNDING

No funding was received from any source for any part of this work.

References

1. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. *J Clin Epidemiol*. 1999; **52**(6): 487-97.
2. Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I. Size and quality of randomised controlled trials in head injury: review of published studies. *BMJ*. 2000; **320**(7245): 1308-11.
3. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. *BMJ*. 1998; **317**(7167): 1181-4.
4. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. *JAMA*. 2002; **287**(21): 2801-4.
5. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ*. 2001; **323**(7303): 42-6.
6. Montori VM, Wang YG, Alonso-Coello P, Bhagra S. Systematic evaluation of the quality of randomized controlled trials in diabetes. *Diabetes Care*. 2006; **29**(8): 1833-8.
7. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA*. 1996; **276**(8): 637-9.
8. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010; **340**: c869.
9. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet*. 2001; **357**(9263): 1191-4.
10. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. *Syst Rev*. 2012; **1**: 60.
11. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to

- 1 the Consolidated Standards of Reporting Trials (CONSORT) checklist. *Control Clin Trials*. 2002; **23**(4):
2 380-8.
3
4
5 12. Haidich AB, Birtsoy C, Dardavessis T, Tirodimos I, Arvanitidou M. The quality of safety
6 reporting in trials is still suboptimal: survey of major general medical journals. *J Clin Epidemiol*. 2011;
7 **64**(2): 124-35.
8
9
10 13. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading
11 medical journals since the revised CONSORT statement. *Contemp Clin Trials*. 2005; **26**(4): 480-7.
12
13 14. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of
14 randomized trials: a comparative before-and-after evaluation. *JAMA*. 2001; **285**(15): 1992-5.
15
16 15. Agha R, Cooper D, Muir G. The reporting quality of randomised controlled trials in surgery: a
17 systematic review. *Int J Surg*. 2007; **5**(6): 413-22.
18
19 16. Balasubramanian SP, Wiener M, Alshameeri Z, Tiruvoipati R, Elbourne D, Reed MW. Standards
20 of reporting of randomized controlled trials in general surgery: can we do better? *Ann Surg*. 2006; **244**(5):
21 663-7.
22
23 17. Gray R, Sullivan M, Altman DG, Gordon-Weeks AN. Adherence of trials of operative
24 intervention to the CONSORT statement extension for non-pharmacological treatments: a comparative
25 before and after study. *Ann R Coll Surg Engl*. 2012; **94**(6): 388-94.
26
27 18. Sinha S, Ashby E, Jayaram R, Grocott MP. Quality of reporting in randomized trials published in
28 high-quality surgical journals. *J Am Coll Surg*. 2009; **209**(5): 565-71 e1.
29
30 19. McCulloch P, Taylor I, Sasako M, Lovett B, Griffin D. Randomised trials in surgery: problems
31 and possible solutions. *BMJ*. 2002; **324**(7351): 1448-51.
32
33 20. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to
34 randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med*. 2008;
35 **148**(4): 295-309.
36
37 21. Thomson-Reuters. ISI Web of Knowledge. 2012 [cited 18 September 2012]; Available from:
38 <http://wok.mimas.ac.uk/>
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011.
23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996; **17**(1): 1-12.
24. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. *BMJ*. 1996; **313**(7052): 253-8.
25. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *Cochrane Database Syst Rev*. 2012; **11**: MR000030.
26. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med*. 1991; **325**(7): 445-53.
27. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA*. 1995; **273**(18): 1421-8.
28. Wennberg DE, Lucas FL, Birkmeyer JD, Bredenberg CE, Fisher ES. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. *JAMA*. 1998; **279**(16): 1278-81.
29. Cook JA, McCulloch P, Blazeby JM, Beard DJ, Marinac-Dabic D, Sedrakyan A. IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage. *BMJ*. 2013; **346**: f2820.
30. McCulloch P. How to improve surgical research. *BMJ*. 2011; **343**: d4121.
31. Brown T. It's Time for AllTrials Registered and Reported. *Cochrane Database Syst Rev*. 2013; **5**: ED000057.




Figure 1. Flow diagram of study selection.
120x90mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APPENDIX S1

Search strategy for medical journals

Databases: **PubMed** <1948 to Present>

Search Strategy:

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13	-----	
14		
15	1	randomized controlled trial [pt] (319493)
16	2	controlled clinical trial [pt] (83422)
17	3	randomized [tiab] (258027)
18	4	placebo [tiab] (138836)
19	5	drug therapy [sh] (1500313)
20	6	randomly [tiab] (177741)
21	7	trial [tiab] (298335)
22	8	groups [tiab] (1179377)
23	9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 (2938926)
24	10	animals [mh] NOT humans [mh] (3648479)
25	11	#9 NOT #10 (2515800)
26	12	2011[dp] (980498)
27	13	"N Engl J Med"[Journal] (66892)
28	14	(Surgery OR Surgical OR Surgeon) (3293015)
29	15	#11 AND #12 AND #13 AND #14 (54)
30		
31		
32		
33		
34	-----	
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

NB: searches 1 to 11 are taken directly from the Cochrane Handbook, box 6.4a. These steps form the 'Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format'.

COMPRESSED SEARCH – New England Journal of Medicine (NEJM) – 54 RESULTS

((randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])) AND (2011[dp]) AND (surgery OR surgical OR surgeon) AND ("N Engl J Med"[Journal])

Search strategy for surgical journals

Databases: **PubMed** <1948 to Present>

Search Strategy:

1	randomized controlled trial [pt]	(319493)
2	controlled clinical trial [pt]	(83422)
3	randomized [tiab]	(258027)
4	placebo [tiab]	(138836)
5	drug therapy [sh]	(1500313)
6	randomly [tiab]	(177741)
7	trial [tiab]	(298335)
8	groups [tiab]	(1179377)
9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	(2938926)
10	animals [mh] NOT humans [mh]	(3648479)
11	#9 NOT #10	(2515800)
12	2011[dp]	(980498)
13	"Ann Surg"[Journal]	(27081)
14	#11 AND #12 AND #13	(109)

NB: searches 1 to 11 are taken directly from the Cochrane Handbook, box 6.4a. These steps form the 'Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format'.

COMPRESSED SEARCH – Annals of Surgery – 109 RESULTS

((randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])) AND (2011[dp]) AND ("Ann Surg"[Journal])

APPENDIX S2

CRITERIA FOR SELECTING STUDIES

INCLUSION CRITERIA:

- Randomized clinical trial
- Human subjects
- Published in 2011 (this can include EITHER print or e-publication during 2011)
- Primary aim of study considers an interventional therapy
 - o For the purpose of this study, this is defined as a therapy involving:
 - Some element of invasion or trauma to the body
 - The requirement for operator skill to achieve a successful requirement
 - With the exception of an intervention being used purely to deliver a pharmacologic treatment (i.e. catheter delivered drug)

EXCLUSION CRITERIA:

- One of the trial arms does not contain an interventional therapy as defined above
- Drug treatment as the primary intervention, even in a surgical population (e.g. chemotherapy for ovarian cancer)
- Trial has previously been reported

EXAMPLES of excludable studies:

- Drug/fluid/blood in both arms (no interventional therapy)
- Psychological/educational training in both arms (no interventional therapy)
- Intervention in one arm but only used to deliver a drug (e.g. catheter infusion of local anaesthetic or delivery of thrombolysis)
- Endoscopy, colonoscopy enteroscopy in both arms with no explicit intention stated to use intervention therapy (i.e. procedure was intended for imaging purposes)
- Subgroup analysis of a previously reported trial
- Long term follow-up data of a previously reported trial

Journal Information

Journal	Abbreviated code	2011 ISI Impact Factor	Number of Results	Number of included RCTs
MEDICAL				
New England Journal of Medicine	NEJM	53.298	54	7
The Lancet	LANC	38.278	58	6
Journal of the American Medical Association	JAMA	30.026	41	4
Annals of Internal Medicine	ANIM	16.733	19	1
PLOS Medicine	PLOS	16.269	4	2
BMJ	BMJ	14.093	26	2
Archives of Internal Medicine	ARIM	11.462	14	0
Canadian Medical Association Journal	CMAJ	8.217	12	0
SURGICAL				
Annals of Surgery	ANSU	7.492	109	11
American Journal of Transplantation	AJT	6.394	76	0
Endoscopy	ENDO	5.210	63	3
Journal of Neurology, Neurosurgery and Psychiatry	JNNP	4.764	93	2
British Journal of Surgery	BJS	4.606	121	13
Journal of the American College of Surgeons	JACS	4.549	59	0
American Journal of Surgical Pathology	AJSP	4.352	24	0
Archives of Surgery	ARCH	4.239	58	3
TOTAL			831	54

APPENDIX S3

Modified CONSORT Number	Point	Guideline to use when scoring	Present in 2008 NPT?	2008 NPT Extension points to be aware of when scoring
1a	Title and abstract	2010	Yes (combined a/b)	In the abstract, description of the experimental treatment, comparator, care providers, centers, and blinding status
1b				
2a	Background and objectives	2010	Yes (combined a/b)	N/A
2b				
3a	Trial design	2010	No	N/A
3b				
4a	Participants	2010	Yes (combined a/b)	When applicable, eligibility criteria for centers and those performing the interventions
4b				
5	Interventions	2010	Yes (split a/b/c)	Precise details of both the experimental treatment and comparator
5a				Description of the different components of the interventions and, when applicable, descriptions of the procedure for tailoring the interventions to individual participants
5b				Details of how the interventions were standardized
5c				Details of how adherence of care providers with the protocol was assessed or enhanced
6a	Outcomes	2010	Yes (combined a/b)	N/A
6b				
7a	Sample size	2010	Yes (combined a/b)	When applicable, details of whether and how the clustering by care providers or centers was addressed
7b				
8a	Randomisation sequence generation	2010	Yes (combined a/b)	When applicable, how care providers were allocated to each trial group
8b				
9	Allocation concealment mechanism	2010	Yes	N/A
10	Randomisation implementation	2010	Yes	N/A

Modified CONSORT Number	Point	Guideline to use when scoring	Present in 2008 NPT?	2008 NPT Extension points to be aware of when scoring
11a	Blinding	2010	Yes (split a/b)	Whether or not those administering co-interventions were blinded to group assignment
11b				If blinded, method of blinding and description of the similarity of interventions
12a	Statistical methods	2010	Yes (combined a/b)	When applicable, details of whether and how the clustering by care providers or centers was addressed
12b				
13a	Participant flow	2010	Yes (combined a/b)	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center
13b				
New in NPT	Implementation of intervention	<u>2008 NPT</u>	Yes	Details of the experimental treatment and comparator as they were implemented
14a	Recruitment	2010	Yes (combined a/b)	N/A
14b				
15a	Baseline data	2010	Yes	(2010 Point 15) N/A
15b		<u>2008 NPT</u>	Yes	(2008 NPT Extension) When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group
16	Numbers analysed	2010	Yes	N/A
17a	Outcomes and estimation	2010	Yes (combined a/b)	N/A
17b				
18	Ancillary analyses	2010	Yes	N/A
19	Harms	2010	Yes	N/A
20	Limitations	2010	No	N/A
21	Generalisability	2010	Yes	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial

22	Interpretation	2010	Yes	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group
23	Registration	2010	No	N/A
24	Protocol	2010	No	N/A
25	Funding	2010	No	N/A

Tables 1 and 2. Tables showing the modified CONSORT scoring checklist to take into account the 2008 NPT extension guidelines whilst scoring against the general points in the 2010 standard CONSORT statement

ELIVS Number	Point	Further detail
E1	Treatment allocation	Was it randomised?
E2	Randomisation method	Appropriate method of randomisation described
E3	Allocation concealment	Appropriate steps taken to conceal allocation sequence
E4	Post-randomisation baseline comparison	Usually located in a table. Showing both groups are similar post randomisation for all known prognostically important factors
E5	Patients blinded	Method of blinding described and is appropriate
E6	Evaluators blinded	Method of blinding described and is appropriate
E7i	Handling and reporting of withdrawals	Full accounting for all patients who entered the trial
E7ii	Intention to treat analysis	Per protocol analysis can be provided in addition but there must also be ITT analysis

Table 3. Extended Linde Internal Validity Scale



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n/a
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix S2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	n/a
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	n/a

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	n/a
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	n/a
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	n/a
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	n/a
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	n/a
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>